matechs1.htm
As filed
with the Securities and Exchange Commission on December 15, 2008
Registration
No. 333-______
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
S-1
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
MATECH
CORP.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
3823
|
|
95-4622822
|
(State
or other jurisdiction of
incorporation
or organization)
|
|
(Primary
Standard Industrial
Classification
Code Number)
|
|
(IRS
Employer
Identification
No.)
|
11661 San
Vicente Boulevard, Suite 707
Los
Angeles, CA 90049
(310)
208-5589
(Address,
including zip code, and telephone number,
including
area code, of registrant’s principal executive offices)
Robert M.
Bernstein
11661 San
Vicente Boulevard, Suite 707
Los
Angeles, CA 90049
(310)
208-5589
(Name,
address, including zip code, and telephone number,
including
area code, of agent for service)
Approximate
Date of Proposed Sale to the Public:
As
promptly as practicable after this registration statement becomes
effective.
If any of
the securities being registered on this Form are to be offered on a delayed
or continuous basis pursuant to Rule 415 under the Securities Act, check
the following box: ý
If this
Form is filed to register additional securities for an offering pursuant to
Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. o
If this
Form is a post-effective amendment filed pursuant to
Rule 462(c) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective
registration statement for the same offering. o
If this
Form is a post-effective amendment filed pursuant to
Rule 462(d) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective
registration statement for the same offering. o
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See
the definitions of “large accelerated filer,” “accelerated filed” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer
|
o
|
Accelerated
filer
|
o
|
Non-accelerated
filer
|
o (Do not check if
a smaller reporting company)
|
Smaller
reporting company
|
ý
|
Calculation
of Registration Fee
Title
of Each Class of Securities to be Registered
|
|
Amount
to be Registered
|
|
|
Proposed
Maximum Offering Price Per Unit
|
|
|
Proposed
Maximum Aggregate Offering Price1
|
|
|
Amount
of Registration Fee
|
|
Class
A Common Stock, $0.001 par value per share
|
|
|
19,607,943 |
|
|
$ |
2.10 |
|
|
$ |
41,176,681 |
|
|
$ |
1,619 |
|
Warrants
to Purchase Class A Common Stock
|
|
|
18,050,200 |
|
|
$ |
02 |
|
|
$ |
0 |
|
|
$ |
0 |
|
Class
A Common Stock issuable upon exercise of warrants
|
|
|
18,050,200 |
|
|
$ |
0.203 |
|
|
$ |
3,610,040 |
|
|
$ |
142 |
|
Convertible
Debentures
|
|
|
1,000,000 |
|
|
$ |
04 |
|
|
$ |
0 |
|
|
$ |
0 |
|
Class
A Common Stock issuable upon conversion of Convertible
Debentures
|
|
|
10,000,0005 |
|
|
$ |
0.106 |
|
|
$ |
1,000,000 |
|
|
$ |
40 |
|
Total
|
|
|
66,708,343 |
|
|
|
|
|
|
$ |
45,786,721 |
|
|
$ |
1,801 |
|
The
registrant hereby amends this registration statement on such date or dates as
may be necessary to delay its effective date until the registrant shall file a
further amendment which specifically states that this registration statement
shall thereafter become effective in accordance with Section 8(a) of the
Securities Act of 1933, or until this registration statement shall become
effective on such date as the Securities and Exchange Commission acting pursuant
to said Section 8(a) may determine.
The
information in this prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This prospectus is
not an offer to sell these securities and it is not soliciting an offer to buy
these securities in any state where the offer or sale is not
permitted.
1 Estimated solely for the purpose of
calculating the registration fee pursuant to Rule 457(o) under the Securities
Act of 1933.
2 Pursuant to Rule 457(g) under the Securities
Act of 1933, no registration fee is payable for warrants that are registered for
distribution in the same registration statement as the securities to be offered
pursuant thereto.
3 Calculated based upon the exercise price of
$0.20 per share pursuant to Rule 457(g) of the Securities Act of
1933.
4 Pursuant to Rule 457(i) under the Securities
Act of 1933, no registration fee is payable for convertible securities that are
registered for distribution in the same registration statement as the securities
to be offered pursuant thereto.
5 Calculated based upon the conversion price of
$0.10 per share of common stock rather than the conversion price of 50% of the
average closing price of our common stock for the ten trading days immediately
preceding the conversion date as that amount cannot currently be
ascertained. This amount may be expanded to include interest which is
potentially convertible into shares but which amount cannot currently be
ascertained.
6 Calculated based upon the conversion price of
$0.10 per share of common stock pursuant to Rule 457(f) of the Securities Act of
1933.
PRELIMINARY
PROSPECTUS
SUBJECT
TO COMPLETION, DATED DECEMBER 15, 2008
18,050,200
WARRANTS
1,000,000
CONVERTIBLE DEBENTURES
19,607,943
SHARES OF COMMON STOCK
MATECH
CORP.
This
prospectus covers the resale by selling securityholders of up to 18,050,200
warrants, 1,000,000 convertible debentures, and 19,607,943shares of our common
stock.
These
securities will be offered for sale from time to time by the selling
securityholders identified in this prospectus in accordance with the terms
described in the section of this prospectus entitled “Plan of
Distribution.” We will not receive any of the proceeds from the sale
of the common stock by the selling securityholders.
Our
securities are not listed on any national securities exchange. Our
common stock is currently quoted on the over-the-counter electronic
Bulletin Board under the symbol “MTCH.OB.” Our warrants and
convertible debentures do not trade on any securities exchange or electronic
trading system The last reported per share price for our common stock
was $2.10, as quoted on the over-the-counter electronic Bulletin Board
on December 9, 2008.
Investing
in our common stock involves risks. See “Risk Factors” beginning on
page 3 to read about factors you should consider before buying shares of our
common stock.
Neither
the Securities and Exchange Commission nor any state securities commission has
approved or disapproved of these securities or determined if this prospectus is
truthful or complete. Any representation to the contrary is a
criminal offense.
The date
of this Prospectus is December 15, 2008
You
should rely only on the information contained in this prospectus. We
have not authorized anyone to provide you with information different from that
contained in this prospectus. We are offering to sell, and seeking
offers to buy, shares of common stock only in jurisdictions where offers and
sales are permitted. The information contained in this prospectus is
accurate only as to the date of this prospectus, regardless of the time of
delivery of the prospectus or of any sale of the common stock. It is important
for you to read and consider all information in this prospectus in making your
investment decision.
Unless
the context requires otherwise, in this prospectus the terms “we,” “us,” and
“our” refer to Matech Corp., a Delaware corporation.
This
summary highlights selected information in this prospectus. To better
understand this offering, and for a more complete description of the offering,
you should read this entire prospectus carefully, including the “Risk Factors”
section and the financial statements and the notes to those statements, which
are included elsewhere in this prospectus.
Our
Company
We
research and develop technologies that detect and measure metal fatigue.
We have developed two products. Our two products are the Fatigue Fuse and
Electrochemical Fatigue Sensor. We generate very little revenue from the
sale and licensing of our products, and thus we are a development stage
company.
We were
formed as a Delaware corporation on March 4, 1997. We are the successor to
the business of Material Technology, Inc., a Delaware corporation, also doing
business as Tensiodyne Scientific, Inc. Material Technology, Inc. was the
successor to the business of
Tensiodyne
Corporation that began developing the Fatigue Fuse in 1983. Our two
predecessors, Tensiodyne Corporation and Material Technology, Inc. were engaged
in developing and testing our Fatigue Fuse and, beginning in 1993, developing
our Electrochemical Fatigue Sensor.
Our
principal executive offices are located at 11661 San Vicente Blvd., Suite 707,
Los Angeles, California, 90049, and our telephone number is (310)
208-5589.
The
Offering
Securities
Offered by Selling Securityholders
|
48,829,193 shares
of our common stock1
|
|
|
Shares
of Common Stock Outstanding
|
|
|
|
Use
of Proceeds
|
We
will not receive any of the proceeds from the sale of the common stock by
the selling securityholders.
|
|
|
Risk
Factors
|
You
should carefully consider all of the information contained in this
prospectus, and in particular, you should evaluate the specific risks set
forth under “Risk Factors.”
|
1 Includes
19,607,943 shares of common stock, 18,050,200 shares of common stock issuable
upon exercise of warrants, and 10,000,000 shares of common stock issuable upon
conversion of convertible debentures.
2 Does not
include any shares of common stock issuable upon exercise of outstanding
warrants or options or conversion of convertible securities.
Summary
Financial Data
The
following table sets forth our summary consolidated financial data for the nine
months ended September 30, 2008 and September 30, 2007 and the fiscal years
ended December 31, 2007 and December 31, 2006. This information
should be read in conjunction with the financial statements (including the
related notes thereto) appearing elsewhere in this prospectus.
|
|
For
the Nine Months Ended September 30, 2008
|
|
|
For
the Nine Months Ended September 30, 2007
|
|
|
For
the Year Ended December 31, 2007
|
|
|
For
the Year Ended December 31, 2006
|
|
|
|
(unaudited)
|
|
|
(unaudited)
|
|
|
(audited)
|
|
|
(audited)
|
|
Statement
of Operations Data
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$ |
30,359 |
|
|
$ |
146,745 |
|
|
$ |
201,917 |
|
|
$ |
39,446 |
|
Research
and development costs
|
|
|
423,428 |
|
|
|
3,533,343 |
|
|
|
3,701,966 |
|
|
|
902,446 |
|
General
and administrative expenses
|
|
|
26,619,102 |
|
|
|
82,608,673 |
|
|
|
98,557,941 |
|
|
|
138,892,926 |
|
Operating
loss
|
|
|
(27,012,171 |
) |
|
|
(85,995,271 |
) |
|
|
(102,057,990 |
) |
|
|
(139,755,926 |
) |
Net
loss
|
|
|
(19,338,972 |
) |
|
|
(84,336,192 |
) |
|
|
(73,396,579 |
) |
|
|
(177,884,101 |
) |
Net
loss per share (basic and diluted)
|
|
|
(0.12 |
) |
|
|
(0.83 |
) |
|
|
(0.68 |
) |
|
|
(40.10 |
) |
Weighted
average common shares outstanding (basic and diluted)
|
|
|
156,873,303 |
|
|
|
101,671,169 |
|
|
|
107,708,004 |
|
|
|
4,435,708 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance
Sheet Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
|
441,076 |
|
|
|
987,284 |
|
|
|
809,710 |
|
|
|
129,296 |
|
Total
assets
|
|
|
1,128,852 |
|
|
|
2,928,147 |
|
|
|
2,425,280 |
|
|
|
432,780 |
|
Current
liabilities
|
|
|
965,775 |
|
|
|
524,057 |
|
|
|
691,380 |
|
|
|
542,802 |
|
Long-term
liabilities
|
|
|
5,772,022 |
|
|
|
33,647,393 |
|
|
|
13,549,275 |
|
|
|
46,443,413 |
|
Total
stockholders’ deficit
|
|
|
(5,609,770 |
) |
|
|
(31,244,128 |
) |
|
|
(11,816,200 |
) |
|
|
(46,554,260 |
) |
Investing
in our securities involves a high degree of risk. You should carefully consider
the following risk factors and all other information contained in this
prospectus before purchasing our securities. The risks and uncertainties
described below are not the only ones facing us. Additional risk and
uncertainties of which we are unaware, or that we currently deem immaterial,
also may become important factors that affect us. If any of the following risks
occur, our business, financial condition, or results of operations could be
materially and adversely affected. In that event, the trading price of our
common stock could decline, and you may lose some or all of your
investment.
Risks
Related to Our Business and Industry
We
have operated at a loss since inception; we expect future losses and we may not
achieve or maintain profitability.
We have
had only limited revenues to date, and have incurred only losses as we have
funded the research and development of our technology and continue to fund the
development and marketing of our products and services. As of
September 30, 2008, we have an accumulated deficit of approximately
$332,547,374. In view of this deficit, our business and prospects
would be significantly impaired if we were to sustain any significant shortfall
in projected revenues.
We intend
to invest our financial and other resources heavily in building management,
sales, and marketing, and in funding further research and development of our
technology. We do not expect to generate profits from operations for
a significant period of time, if at all, and if we do not achieve and sustain
profitability, our business will suffer. In addition, even if we
achieve profitability, our growth rates may not be sustainable. Our
future performance will depend upon a number of factors, including our ability
to:
|
·
|
Execute
our business and marketing
strategy;
|
|
·
|
Develop
a customer base;
|
|
·
|
Successfully
market our products and services to customers at prices that will generate
the significant revenue we will need to achieve and maintain
profitability;
|
|
·
|
Continue
to develop and upgrade our
technology;
|
|
·
|
Respond
to competitive demands;
|
|
·
|
Provide
superior technical support; and
|
|
·
|
Attract,
retain, and motivate qualified
personnel.
|
We
need financing to run our business
Our
biggest challenge is funding the continued research and development and
commercialization of our products until we can generate sufficient revenue to
support our operations. We will need to raise additional capital to
finance future activities and no assurances can be made that current or
anticipated future sources of funds will enable us to finance future
operations. In light of these circumstances, substantial doubt exists
about our ability to continue as a going concern.
Our
prospective customers often take a long time to evaluate our products, with this
lengthy and variable sales cycle making it difficult to predict our operating
results.
It is
difficult to forecast the timing and recognition of revenues from sales of our
products because prospective customers often take significant time evaluating
our products before purchasing them. The period between initial
customer contact and a purchase by a customer may be more than one
year. During the evaluation period, prospective customers may decide
not to purchase or may scale down proposed orders of our products for various
reasons, including:
· Reduced
need to upgrade existing systems;
· Introduction
of products by our competitors;
· Lower
prices offered by our competitors; and
· Changes
in budgets and purchasing priorities.
Our
prospective customers routinely require education and training regarding the use
and benefit of our products. This may also lead to delays in
receiving customers’ orders.
An
investment in the securities is very speculative and may not offer the same
diversity as an investment in a larger better capitalized company.
Because
we are a small company that has only recently commenced product sales, our
business objectives must be considered speculative, and we may never achieve our
objectives. Thus, investors may never realize a substantial or any
return on investment whatsoever, and could lose their entire
investment. In addition, unlike larger companies, our business may
not be adequately diversified regarding the products and services we offer or
the customer base. To the extent that our funds are invested
predominately in a single product or service, or even a few products or
services, there is increased exposure to us and to investors.
Our
failure to raise additional capital could reduce our ability to complete and
harm our business.
The
expansion and development of our business will require us to raise additional
capital. We cannot assure investors that we will be able to raise
additional capital on favorable terms, if at all. We currently do not
have any commitment with respect to any additional capital. In
addition, we currently have no loan commitment from, or lines of credit with,
banks or other financial institutions. If we are unable to raise
capital in the future on acceptable terms, we may not be able to continue to
operate our business and could be forced to discontinue business
operations.
Our
future operating results are difficult to forecast, may fluctuate and could fall
below our expectations.
Since we
have had only a limited operating history, and because of the rapidly evolving
nature of this industry and market, we may have difficulty in accurately
forecasting our revenue in any given period. Moreover, our revenues
and operating results may vary significantly from quarter to quarter because of
a number of factors. One factor will be the demand and market
acceptance for our technology and products. If our technology and
products are accepted by the market, another factor will be the size and timing
of customer orders for our products. In any given quarter, sales of
some of our products could involve large financial commitments from a relatively
small number of customers, and cancellation or deferral of these large contracts
would reduce our revenues.
Also, we
may book a large amount of sales in the last month or weeks of a particular
quarter and delays in the closing of sales near the end of a quarter could cause
quarterly revenue to fall short of anticipated levels. Finally, while
a portion of our revenues each quarter may be recognized from previously
deferred revenue, our quarterly performance will depend primarily upon entering
into new contracts to generate revenues for that quarter.
Other
factors that may impact our operating results include the
following:
|
·
|
Increased
expenses, whether related to sales and marketing, product development, or
administration;
|
|
·
|
Delays
in introducing new products;
|
|
·
|
The
announcement or introduction of new products by our
competitors;
|
|
·
|
The
capital and expense budgeting decisions of our
customers;
|
|
·
|
Market
acceptance of our products and
services;
|
|
·
|
Cost
related to acquisitions of new technologies or
businesses;
|
|
·
|
The
amount and timing of expenditures related to expansion of our
operations;
|
|
·
|
The
ability of our products to perform favorably relative to competitive
benchmarks;
|
|
·
|
Changes
in the timing of product orders caused by unexpected delays in the
introduction of products by our customer or by the life cycles of
customers’ products ending earlier than we
anticipated;
|
|
·
|
Competitive
pressures resulting in lower average selling
prices;
|
|
·
|
The
rescheduling or cancellation of customer
orders;
|
|
·
|
The
unanticipated loss of any strategic
relationship;
|
|
·
|
Seasonal
fluctuations in governmental contracting and purchasing habits;
and
|
|
·
|
Cost
associated with protecting our intellectual
property.
|
Any one
or more of these factors could result in our failing to achieve future revenues
and profitability. Because most operating expenses are relatively
fixed in the short term, we may be unable to adjust spending sufficiently in a
timely manner to compensate for any unexpected sales shortfall, which could
materially adversely affect quarterly results of
operations. Accordingly, we believe that period-to-period comparisons
of our results of operations should not be relied
upon as
an indication of future performance. In addition, the result of any
quarterly period is not indicative of results to be expected for a full fiscal
year.
If
contract cancellations are larger than we allow for, our business may
suffer.
We are
exposed to the risk of contract cancellations from our
customers. Moreover, the risk of contract cancellations may increase
if our industry adopts new platforms or standards or there are changes in
government regulations. We do not have and do not expect to establish
reserves for contract cancellations. If we experience many contract
cancellations, it would significantly impact our business.
We
are subject to liability claims and we may not have sufficient insurance
coverage.
As of the
date of this prospectus, we do not have liability coverage; however, we plan to
obtain liability insurance that will be adequate for the size and type of
business we are in. We cannot ensure such insurance will be
sufficient to cover potential claims or that adequate levels of coverage will be
available in the future at a reasonable cost. If we are partially or
completely uninsured, successful claims against us will have a material adverse
impact on our financial condition and reputation.
We
cannot accurately predict whether our products will achieve market acceptance,
the future growth rate of this market or its ultimate size.
Our
products are new and are meant to provide a relatively low-cost, accurate
solution for private and public entities to determine the integrity of
infrastructure. Because we have only recently begun to sell products,
we believe that most potential customers are unaware of our products and their
capabilities and may thus be slow in accepting and deploying our
solutions. This makes our prospects difficult to
forecast. While we intend to devote significant resources to
promoting awareness of our products and technology and the solution these
products provide, these efforts may not be sufficient to build market awareness
of the need for our products. In addition, because the market for our
products and services is relatively new and rapidly evolving, we have limited
insight into trends that may emerge and affect our business. We may
make errors in predicting and reacting to relevant business trends, which could
harm our business. If a significant market for our products and
technology fails to develop, or if our products and technology fail to achieve
broad market acceptance, our business would be seriously harmed.
The
market for our products and technology may not grow as quickly as we anticipate,
which would cause our revenues to fall below expectations
The market for our
products and services is relatively new and evolving. Our ability to
achieve sustained revenue growth and profitability in the future will depend to
a large extent upon the demand for infrastructure testing methods. We
cannot assure investors that the market for our products and services will
develop or grow at a rate sufficient to support our business. If the
market for such products fails to develop, or develops more slowly than we
expect, or if our technology and products do not achieve market acceptance, even
if such market does develop, our business would be significantly
harmed. Demand for our products is also dependent
upon
our
customers’ success in effectively implementing and utilizing our technology, as
well as the willingness of such customers to pay for infrastructure
testing.
Many of
our potential customers have made significant investments in existing technology
and might incur significant costs in switching to other products, which could
substantially inhibit the growth of the market for our products and
services. If this market fails to grow, or grows more slowly than we
expect, our sales will be adversely affected.
Because
we expect to incur significant increases in our operating expenses in the
foreseeable future, we may not be able to achieve or sustain
profitability.
We intend
to substantially increase our operating expenses for the foreseeable future as
we:
|
·
|
Increase
our domestic and international sales and marketing
activities;
|
|
·
|
Increase
our research and development activities to advance our existing
technology, products, and services, and to develop new technology,
products, and services;
|
|
·
|
Hire
additional personnel, including engineers, technical staff, and sales
force; and
|
|
·
|
Upgrade
our operational and financial systems, procedures, and
controls.
|
We will
have to increase our revenues significantly in order to achieve profitability in
the face of such increased expenditures. These expenses may be
incurred before we can generate any revenues from the increased
spending. If we do not significantly increase revenues from these
efforts, our business and operating results would be negatively
impacted.
Our
growth is expected to place a significant strain on our management systems and
resources. Failure to manage our growth may harm our ability to
market and sell our products and develop new products.
We will
have to plan and manage our growth effectively in order to offer our products
and services and achieve revenue growth in a rapidly evolving
market. We expect that anticipated future growth will place a
significant strain on our management, financial controls, operations, personnel,
and other resources, and we may not be able to effectively manage our growth in
the future. As we continue to increase the scope of our operations,
we will have to add more members of our management team and additional
employees. For us to effectively manage our growth, we will have to
do the following:
|
·
|
Identify
and implement adequate operations support systems on a timely basis, and
expand and upgrade these systems as our business
grows;
|
|
·
|
Improve
our reporting systems and
procedures;
|
|
·
|
Install
new management and information control systems;
and
|
|
·
|
Expand,
train, and motivate our workforce.
|
If we are
unable to manage the expansion of our business effectively, our financial
performance will be harmed.
We
have limited management staff, and if we lose our key personnel or are unable to
attract and retain additional personnel, our business and ability to compete
will be harmed.
Our
success substantially depends upon the continued availability and contributions
of our management team. Due to the complexity of our proposed
products and services, heavy reliance will also be placed on the skills and
talents of engineering and technical personnel. Important factors
that could cause the loss of key personnel include:
|
·
|
We
do not have employment agreements with a majority of our key engineering
and technical personnel; and
|
|
·
|
We
do not maintain key-person life insurance on any of our employees: the
death, incapacity, or other loss of key personnel, or an inability to
attract qualified personnel in a timely manner, could cause an adverse
impact on our technology and product development and harm our ability to
execute our business plan in a timely
manner.
|
We
proposed to recruit a significant number of additional executives and personnel
to support our various departments such as, sales, marketing, administrative,
customer support, and research and development over the next 12 months,
including a vice president of marketing. The recruitment of qualified
executives and personnel for various departments is highly competitive in our
industry. This has been demonstrated by a recent significant shortage
of persons possessing the requisite managerial or technical background to manage
and/or support a similar company, or to sell, support, and develop similar
products effectively. If we cannot attract sufficient number of
qualified personnel, our business will not be able to
grow. Competition for skilled personnel is intense, and we may not be
able to attract, assimilate, or retain highly qualified personnel in the
future. These problems may be intensified in the foreign markets in
which we intend to operate, and the absence of a pool of qualified and talented
persons in any of these foreign markets could significantly hamper our foreign
operations, which is expected to comprise a significant segment of
business.
If
we fail to protect our intellectual property rights adequately, we could lose
these rights and our business may be seriously harmed.
Our
success and ability to compete are dependent on our ability to develop and
maintain the proprietary aspects of our technology and intellectual property
rights. We rely on a combination of patent, trademark, trade secret,
copyright law, and contractual restrictions to protect the proprietary aspects
of our technology and to distinguish our products from those of our
competitors. The use by others of our proprietary rights could
materially harm our business. Any future applications may not result
in the issuance of any patent or trademarks.
Despite
our efforts to protect our proprietary rights, unauthorized parties may attempt
to copy aspects of our products or to obtain and use information that we regard
as proprietary. Patent, trademark, copyright and trade secret laws,
and confidentiality and other contractual provisions afford only limited
protection and may not adequately protect our rights or permit us to gain or
keep any competitive advantage. We will face numerous risks in
protecting our intellectual property rights, including the
following:
|
·
|
Any
patents that we are granted may be challenged or invalidated by our
competitors;
|
|
·
|
Any
pending applications we may have for intellectual property protection may
not issue, or if issued, may not provide meaningful protection for related
products or proprietary rights;
|
|
·
|
We
may not be able to prevent the unauthorized disclosure or use of our
technical knowledge or other trade secrets by employees, consultants, and
advisors;
|
|
·
|
The
laws of foreign countries may not protect our intellectual property rights
to the same extent as the laws of the United States, and mechanisms for
enforcement of intellectual property rights may be inadequate in foreign
countries;
|
|
·
|
Our
competitors may produce competitive products or services that do not
unlawfully infringe upon our intellectual property rights;
and
|
|
·
|
We
may be unable to successfully identify or prosecute unauthorized uses of
our technology.
|
Our means
of protecting our proprietary rights may prove to be inadequate and competitors
may independently develop similar or superior technology. Policing
unauthorized use of our products is difficult, and we cannot be certain that the
steps we have taken will prevent misappropriation of our
technology. We may have to file law suits in the future in order to
attempt to enforce our intellectual property rights, to protect our trade
secrets, and to determine the validity and scope of the proprietary rights of
others. Any such litigation would be expensive to prosecute and
resolve and would require a significant investment of our management’s time, as
well as financial resources. Furthermore, we intend to sell our
products and services internationally. The laws of many countries do
not protect our proprietary rights to as great an extent as do the laws of the
United States. In addition, we may decide not to seek patent and
other intellectual property protections in certain foreign
countries. In countries where we do not seek such protection,
products incorporating our technology may be lawfully produced and sold without
a license.
We
may be sued by third parties for allegedly infringing on their proprietary
rights.
Our
success and ability to compete also depends on our ability to operate without
infringing upon the proprietary rights of others, and third parties may claim
infringement by us of their intellectual property rights. Companies
that participate in the various segments of the non-destructive testing industry
in which we will compete hold a large number of patents, trademarks, and
copyrights, and are frequently involved in litigation based on allegations of
patent infringement or other violations of intellectual property
rights. Currently, we cannot assure investors that our products do
not infringe issued patents or other intellectual property rights of others, and
we may be subject to legal proceedings and claims from time to time in the
ordinary course of our business, including claims of alleged infringement of the
patents, trademarks, and other intellectual property rights of others by us or
our licensees in connection with their use of our products. Because a
patent application in the United States is not publicly disclosed unless and
until a patent is issued, there may be applications that we do not know about
that may have been filed and that relate to our products. In
addition, we expect that product developers will be increasingly subject to
infringement claims as the number of products and
competitors
in our industry segment grows and the functionality of products in different
industry segments begins to overlap.
Intellectual
property disputes frequently involve highly complex and costly scientific
matters, and each party generally has the right to seek a trial by jury, which
adds additional costs and uncertainties. Accordingly, intellectual
property contests, with or without merit, could be costly and time consuming to
litigate or settle, and could divert management’s attention away from executing
our business plan. In addition, our technology and products may not
be able to withstand any third-party claims or rights against their
use. If we were unable to obtain any necessary license following a
determination of infringement or an adverse determination in litigation or in
interference or other administrative proceedings, we may need to redesign or
reengineer our products to avoid infringing a third party’s patent rights and
could be required to temporarily or permanently discontinue licensing our
products. If we failed to redesign or reengineer our products
successfully or in a timely fashion, or otherwise fail to address any
infringement issues successfully, we will be forced to incur significant costs
and could be prevented from selling or licensing our products. As a
result, our business would be harmed.
We
must expand our sales force and our network of distribution partners in order to
successfully sell our products and services.
In order
to sell our products and services, we will rely on our team of internally
trained direct sales force. We have not yet begun to hire and train
direct sales personnel, and to the extent we have begun to develop direct sales
channels to date, we have relied upon our existing management. We
will need to obtain additional financing in order to invest significant
resources to create and expand our direct sales force. There are no
assurances that we will be successful in expanding our direct sales force nor
are there any assurances that our revenues will increase correspondingly with
the expansion of our direct sales force. If we fail to raise
additional financing, we will not be able to establish and maintain a direct
sales force and our revenues will suffer.
As a
significant portion of our business strategy, we are counting on our ability to
develop relationships with government lobbyists, purchasing agents and
contractors. Accordingly, we will be dependent upon these entities to
assist in promoting acceptance of our products. If we fail to
establish relationships with government representatives, we will have to devote
substantially more of our own resources to the sales and marketing,
implementation, and support of our products than we would
otherwise. In many cases, these parties have extensive relationships
with potential customers and will be able to influence the decisions of these
customers. We will have to rely upon these entities for
recommendations of our products during the evaluation stage of the purchasing
process, as well as for implementation and training services. A
number of our actual and potential competitors operate more mature businesses
than we do, and thus have strong and long-standing relationships with lobbyists,
purchasing agents and contractors. As a result, these entities may be
more likely to recommend such competitors’ products and services. In
addition, such competitors all have relationships with a greater number of
lobbyists, purchasing agents and contractors than we currently have (or expect
to have in the foreseeable future) and thus have access to a broader base of
customers.
Our
failure to establish or maintain these relationships would significantly harm
our ability successfully to sell our products. In addition, we will
need to rely on the industry expertise and reach of these
firms. Therefore, this failure would also harm our ability to develop
industry-specific products. We plan to invest significant resources
to develop these relationships. Our operating results could be
adversely affected if these efforts do not generate revenues necessary to offset
this investment.
We
will rely exclusively on third party manufacturers and suppliers, and losing any
of these could harm our business.
We depend
on the performance of certain selected third parties for product manufacturing
and supplies to complement our services. We currently do not have any
written agreements with any of these third party contract manufacturers or
suppliers. As such, unless we enter into such contracts with these
third party vendors in the future, they could terminate their relationships with
us at any time and it would take several months to find suitable substitutes or
replacements. If we were to lose any of our contract manufacturers or
suppliers, or if any disruption were to occur to the operations of any of their
facilities, whether because of labor difficulties, destruction of or damage to
property, severe weather conditions, or other reasons, our business would be
harmed. We typically do not maintain sufficient inventory to allow it
to fill customer orders without interruption during the time that would be
required to obtain an alternate supplier, and we do not maintain business
interruption insurance to cover the occurrence of such events.
We will
depend on the ability of our manufacturers to adhere to our product, price and
quality specifications and scheduling requirements. Contract
manufacturers frequently experience shortages of supply and could reduce
capacity allocated to us on a relatively short notice. Any delay by a
manufacturer in supplying finished products to us would significantly hurt our
ability to deliver products in a timely and competitive manner. In
addition, our ability to introduce new products into the market will depend
significantly upon the ability of our manufacturers to incorporate any design
changes we wish to introduce. In addition, if any of these third
party manufacturers or suppliers requires any design changes to our products, we
could experience manufacturing delays and lower customer acceptance of our
products.
Our
market is highly competitive and we may not be able to compete
effectively.
Our
market is intensely competitive, subject to rapid change, and significantly
affected by new product introductions and other market activities of industry
participants. In our market, we will compete against different
companies in several market segments, all of which are intensely
competitive. We are in the non-destructive testing (NDT) industry and
provide products and services primarily to local, state and federal government
agencies, but can also sell our products and services to other
companies.
We face
competition from a number of traditional non-destructive testing companies, all
of whom have developed or are developing technologies, products, and services
that will compete with ours. All of our potential competitors are
better capitalized than we are and currently enjoy substantial competitive
advantages, including:
|
· |
Greater
name recognition; |
|
· |
Longer
operating history; |
|
·
|
More
developed distribution channels;
|
|
· |
A
more extensive customer base; |
|
· |
Greater
knowledge of our target market; |
|
· |
Broader
product and service offerings; |
|
· |
Greater
resources for competitive activities, such as research and development,
strategic acquisitions, alliances, joint ventures, sales and marketing,
and lobbying industry, and government standards; |
|
· |
Greater
manufacturing resources; and |
|
· |
More
sales people, technicians and
engineers. |
As a
result, our competitors may be able to respond more quickly to evolving industry
standards and changes in customer requirements, or to devote greater resources
to the development, promotion, and sale of their products than we
can.
Although
we believe that our products will compete favorably on these factors, our market
is relatively new and is developing rapidly. We may not be able to
maintain any competitive position against current and potential competitors,
especially those with significantly greater financial, marketing, services,
technical, and other resources. We cannot assure you that we will be
able to compete successfully in the market.
We
may not be able to improve our technology, products, and services or develop new
technology, products, and services that are acceptable to our customers or the
changing market.
All of
our future plans contemplate our remaining in the non-destructive testing
industry and focusing substantially all of our efforts on developing
non-destructive testing products for infrastructures. This market is
characterized by:
|
·
|
Rapid
technological change;
|
|
·
|
Frequent
new product introductions and
enhancements;
|
|
·
|
Changing
financial resources of customers;
|
|
·
|
Evolving
industry standards; and
|
To the
extent that the U.S. economy undergoes dramatic changes or that other factors
have a severe impact on the industry as a whole, it is likely that such events
would have an even greater impact proportionately on us. In addition,
the technological life cycles of our products are difficult to estimate and may
vary across customer market segments.
Our
existing products will be rendered obsolete if we do not introduce new products
or product enhancements that meet new customer demands, support new standards,
or integrate with new or upgraded versions of packaged
applications. Our future success will depend on our ability to
enhance our existing technology, products, and services and to develop
acceptable new
technology,
products, and services on a timely basis. The development of enhanced
and new technology, products, and services is a complex and uncertain process
requiring high levels of innovation, highly-skilled engineering, and development
personnel and the accurate anticipation of technological and market
trends. We may not be able to identify, develop, market, or support
new or enhanced technology, products, or services on a timely basis, if at
all. Furthermore, any new technology, products, and services may
never gain market acceptance, and we may not be able to respond effectively to
evolving customer demands, technological changes, product announcements by
competitors, or emerging industry standards. Any failure to respond
to these changes or concerns would likely prevent our technology, products, and
services from gaining market acceptance or maintaining market
share.
Risks
Related to this Offering
Compliance
with Sarbanes-Oxley and other new corporate governance and accounting
requirements will require us to incur increased material costs, and the failure
to comply with such requirements will expose us to investigations and sanctions
by regulatory authorities.
We face
recently adopted corporate governance requirements under the Sarbanes-Oxley Act
of 2002 (“SOX”), including new rules and regulations subsequently adopted by the
Securities and Exchange Commission and the Public Company Accounting Oversight
Board. These laws, rules and regulations continue to evolve and may
become more stringent in the future.
SOX in
particular has required changes in the corporate governance, securities
disclosure, auditing and compliance practices of public
companies. Compliance with these numerous new rules and listing
standards related to SOX is likely to increase our general and administrative
costs, and such expenses may increase in the future. In particular,
we will be required to include the management and auditor reports on internal
controls as part of our annual report for our year ending December 31, 2007
under Section 404 of SOX. We are in the process of evaluating our
internal control systems in order to report and attest as required by SOX and to
provide reasonable assurance that our public disclosure will be accurate and
complete. We cannot be certain as to the timing of the completion of
our evaluation, testing and remediation actions or the impact these may have on
our operations. Moreover, there is no available precedent by which to
measure adequacy of SOX compliance. If we are unable to properly
implement the requirements relating to internal controls, financial reporting or
other SOX provisions, we could become subject to sanctions or investigation by
regulatory authorities including the Securities and Exchange
Commission. Any such action could materially harm our reputation,
financial condition and the value and liquidity of our securities. We
anticipate that SOX and rules and regulations related to SOX will increase legal
and financial compliance costs and make our corporate governance activities more
difficult, time-consuming and costly.
If
we fail to establish and maintain an effective system of internal controls, we
may not be able to report our financial results accurately or prevent fraud,
which could result in current and potential shareholders losing confidence in
our financial reporting, which would harm our business and the trading price of
our securities.
Effective
internal controls are necessary for us to provide reliable and timely financial
reports and detect and effectively prevent fraud. If we are unable to
provide reliable financial reporting or we fail to prevent fraud, our business
reputation and results of operations would suffer substantial
harm. Lack of effective internal controls could also cause investors
and stock analysts to lose confidence in our reported financial information,
which would have a negative effect on the trading prices of our
securities. We have already identified the following weaknesses in
our internal control over financial reporting which we must spend time and money
to remediate:
1. We
do not yet have written documentation of our internal control policies and
procedures. Written documentation of key internal controls over financial
reporting is a requirement of Section 404 of the Sarbanes-Oxley Act and will be
applicable to us for the year ending December 31, 2008. Our President and
Chief Financial Officer evaluated the impact of our failure to have written
documentation of our internal controls and procedures on our assessment of our
disclosure controls and procedures and have concluded that the control
deficiency that resulted represented a material weakness.
2. We
do not have sufficient segregation of duties within accounting functions, which
is a basic internal control. Due to our size and nature, segregation of
all conflicting duties may not always be possible and may not be economically
feasible. However, to the extent possible, the initiation of transactions,
the custody of assets and the recording of transactions should be performed by
separate individuals. Our President and Chief Financial Officer evaluated
the impact of our failure to have segregation of duties on our assessment of our
disclosure controls and procedures and have concluded that the control
deficiency that resulted represented a material weakness.
3. We
had a significant number of audit adjustments last fiscal year. Audit
adjustments are the result of a failure of the internal controls to prevent or
detect misstatements of accounting information. The failure could be due
to inadequate design of the internal controls or to a misapplication or override
of controls. Our President and Chief Financial Officer evaluated the
impact of our significant number of audit adjustments last year and have
concluded that the control deficiency that resulted represented a material
weakness.
On
November 27, 2007, our President and Chief Financial Officer concluded that in
valuing previous periods’ non-cash security transactions, we utilized discounts
to the respective share’s trading prices as well as its derivative liabilities
which they have determined are without foundation.
As a
result of this evaluation and conclusion, our President and Chief Financial
Officer in conjunction with our Board of Directors, concluded that previously
issued consolidated financial statements included in our Annual Reports on Form
10-KSB for the fiscal years ended December 31, 2005 and December 31, 2006, as
well as all of our quarterly reports on Form 10-QSB during the 2005 and 2006
fiscal years, could no longer be relied upon. We amended and restated our
financial statements to eliminate all discounts and refiled our Annual Report on
Form 10-KSB for the fiscal year ended December 31, 2006 and its Form 10-QSB for
the quarters ended March
31, 2007
and June 30, 2007. The net effect of the restatements was an increase of
our accumulated deficit at June 30, 2007 from $100,909,477 to
$292,944,478.
Our
President and Chief Financial Officer have discussed this matter with our
current independent registered public accounting firm.
To
remediate the material weaknesses in our disclosure controls and procedures
identified above, in addition to working with our independent auditors, we must
continue to refine our internal procedures to begin to implement segregation of
duties and to reduce the number of audit adjustments.
The
public market for our common stock has been very limited and subject to
significant fluctuations and low trading volume, and accordingly the price of
our securities could be volatile and decline materially, resulting in a
substantial loss of your investment in us.
The
over-the-counter trading market for our common stock has been limited and
subject to frequent fluctuations. There is no assurance an active
trading market for any of our securities will emerge or be sustained, which
could affect your ability to sell your securities and could depress the market
prices of your securities. The stock market in general, and the
market for securities of early-stage companies in particular, has been extremely
volatile. Accordingly, the market price of our securities is likely
to be volatile, and investors in our securities may experience a decrease in
their value including a decline unrelated to our operating performance or
prospects.
The price
of our securities is subject to wide fluctuations in response to a number of
factors including those listed in this “Risk Factors” section. Low
volume or lack of demand for our securities will make it more difficult for you
to sell common stock at favorable prices relative to those you paid for our
securities. You may never be able to resell our common stock at a
favorable price or at a favorable time.
Any
substantial issuance of our shares of common stock pursuant to our outstanding
stock options, warrants and convertible preferred stock or notes will result in
dilution to existing shareholders and could cause the market price of our
securities to decline.
We have
reserved 101,802,382 shares of our common stock available for issuance incident
to any exercises or conversions of our currently outstanding stock options,
warrants, and convertible preferred stock and notes, including 28,050,200 shares
of common stock which are being registered pursuant to this
prospectus. Future material issuances of these shares may reduce our
earnings per share and dilute the percentage ownership of existing shareholders,
which could harm the market price and value of our securities.
We
will continue to be controlled by our current shareholders, who may have
material interests different than those of our new shareholders from this
Offering.
Our
current management and principal shareholders beneficially own approximately 99%
of our outstanding common stock. To the extent our current
shareholders vote similarly, they will for
the
foreseeable future be able to exercise control over many substantial matters
requiring approval by our board of directors or shareholders, including election
of all members of our board of directors, control of our management and
corporate policies, and the outcome of business combinations or other
significant corporate transactions including prevention of a change of control
that may be beneficial to other shareholders. This ownership also
gives our current management and principal shareholders the ability to control
any significant corporate transaction if they vote together as a
group.
Substantial
sales of our securities after this Offering could cause the prices of our
securities to decline materially.
We cannot
predict the effect, if any, that future sales of our outstanding common stock,
or even the availability of our common stock for sale, will have on the market
prices of our securities prevailing from time to time. Sales of
substantial amounts of our common stock in the public market following this
Offering, or the perception that such sales may occur, could harm prevailing
market prices of our securities and impair our ability to raise additional
equity capital.
Our
common stock is deemed to be a “penny stock” and it is more difficult for
investors to resell our common stock.
Our
common stock is a “penny stock” as defined under the Securities Exchange Act of
1934. Trading of our common stock is subject to penny stock
regulations of the SEC that may limit a stockholder’s ability to buy and sell
our common stock.
The penny
stock rules impose additional sales practice requirements on broker-dealers who
sell to persons other than established customers or “accredited investors” who
generally include persons with high net worth or high incomes. Prior
to conducting a transaction in a penny stock, the broker-dealer must deliver a
risk disclosure document in a form prescribed by the SEC that provides
information on penny stocks and the nature and risks involved in the penny stock
market. The broker-dealer also must provide other relevant
information to the customer as well as making a specific written determination
that the penny stock is a suitable investment for the customer and receiving the
customer’s written agreement to the transaction.
These
penny stock requirements could reduce the number of potential investors and
level of trading activity for our securities, which could adversely affect
investor interest in our securities, limit the marketability of our common
stock, and impair the ability of broker-dealers to trade our securities
effectively.
Limited
Access to the Over-the-Counter Bulletin Board Service could disrupt your ability
to trade our securities.
Our
common stock is quoted on the over-the-counter electronic Bulletin
Board. Because there are no automated systems for negotiating trades
on the Bulletin Board service, they are conducted via telephone. In
times of heavy market volume, the limitations of this process may result in a
significant increase in the time it takes to execute investor
orders. Therefore, when investors place market orders – an order to
buy or sell a specific number of shares at the current
market
price – it is possible for the price of a stock to go up or down significantly
during the lapse of time between placing a market order and its
execution.
FORWARD-LOOKING
STATEMENTS
Some of
the statements contained in this prospectus and in the documents we incorporate
by reference that are not purely historical statements discuss future
expectations, contain projections of results of operations or financial
condition or state other forward-looking information. Those
statements are subject to known and unknown risks, uncertainties and other
factors that could cause the actual results to differ materially from those
contemplated by the statements. The “forward-looking” information is
based on various factors and was derived using numerous
assumptions. In some cases, you can identify these so-called
forward-looking statements by words like “may,” “should,” “expect,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” or “potential” or the negative
of those words and other comparable words. You should be aware that
those statements only reflect our predictions. Actual events or
results may differ substantially. Important factors that could cause
our actual results to be materially different from the forward-looking
statements are disclosed under the heading “Risk Factors” in this
prospectus.
Although
we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity, performance
or achievements. We are under no duty to update any of the
forward-looking statements after the date of this prospectus to conform such
statements to actual results.
All
forward-looking statements, express or implied, included in this prospectus and
the documents we incorporate by reference and attributable to us are expressly
qualified in their entirety by this cautionary statement. This
cautionary statement should also be considered in connection with any subsequent
written or oral forward-looking statements that we or any persons acting on our
behalf may issue.
Forward-looking
statements speak only as of the date they are made. You should not put undue
reliance on any forward-looking statements. We assume no obligation to update
forward-looking statements to reflect actual results, changes in assumptions, or
changes in other factors affecting forward looking statements, no inference
should be drawn that we will make additional updates with respect to those or
other forward-looking statements.
The
following discussion of our financial condition and results of operations should
be read in conjunction with our financial statements and the related notes
included elsewhere in this prospectus. This discussion and analysis contains
forward-looking statements that involve risks, uncertainties, and
assumptions. The actual results may differ materially from those
anticipated in these forward-looking statements as a result of certain factors,
including, but not limited to, those presented under “Risk Factors” beginning on
page 3 and elsewhere in this prospectus.
Overview
We
research and develop technologies that detect and measure metal
fatigue. We have developed two products: (1) the Fatigue Fuse; and
(2) the Electrochemical Fatigue Sensor. We generate very little
revenue from the sale and licensing of our products, and thus we are a
development stage company.
Our
biggest challenge is funding the commercialization of our products until we can
generate sufficient revenue to support our operations. We try to keep our
overhead low and utilize outside consultants as much as possible in order to
reduce expenses, and thus far we have been successful in raising enough capital
through loans and financing to fund operations. For the foreseeable
future, we plan to continue to raise capital in this manner.
Our
consolidated financial statements are prepared using the accrual method of
accounting in accordance with accounting principles generally accepted in the
United States of America and have been prepared on a going concern basis, which
contemplates the realization of assets and the settlement of liabilities in the
normal course of business. We have sustained operating losses since our
inception (October 21, 1983). In addition, we have used substantial
amounts of working capital in our operations. Further, at September 30,
2008, the deficit accumulated during the development stage amounted to
approximately $332,547,374.
In view
of these matters, realization of a major portion of the assets in the
accompanying consolidated balance sheet is dependent upon our ability to meet
our financing requirements and the success of our future operations.
During 2007, we received approximately $4,000,000 in private financing,
primarily from the sale of equity and debt securities. Thus far in 2008,
we have received approximately $1,090,000
in private financing, also primarily from the sale of equity and debt
securities. We plan to continue to raise funds through the sale of
our securities for the foreseeable future. In addition in 2007, we
received contracts to inspect certain bridges with nine states which generated
gross revenue of approximately $201,917. Thus far in 2008, we have
received contracts to inspect certain bridges with four entities which generated
gross revenue of approximately $30,359. We have begun marketing our
current technologies while continuing to develop new methods and
applications. We will need to raise additional capital to finance future
activities and no assurances can be made that current or anticipated future
sources of funds will enable us to finance future operations. In light of
these circumstances, substantial doubt exists about our ability to continue as a
going concern. The consolidated financial statements do not include any
adjustments relating to the recoverability and classification
of
recorded
assets or liabilities that might be necessary should we be unable to continue as
a going concern.
Results
of Operations for the Nine Months Ended September 30, 2008 as Compared to the
Nine Months Ended September 30, 2007 (unaudited)
Revenues and Loss from
Operations
Our
revenue, research and development costs, general and administrative expenses,
and loss from operations for the nine months ended September 30, 2008 as
compared to the nine months ended September 30, 2007 are as
follows:
|
|
Nine
Months
Ended
September
30, 2008
|
|
|
Nine
Months
Ended
September
30, 2007
|
|
|
Percentage
Change
|
|
Revenue |
|
$ |
30,359 |
|
|
$ |
146,745 |
|
|
|
(79.31 |
)% |
Research
and Development costs |
|
|
423,428 |
|
|
|
3,533,343 |
|
|
|
(88.02 |
)% |
General
and Administrative expenses |
|
$ |
26,619,102 |
|
|
$ |
82,608,673 |
|
|
|
(67.78 |
)% |
Loss
from operations |
|
$ |
(27,042,530 |
) |
|
$ |
(85,995,271 |
) |
|
|
(68.55 |
)% |
Our
revenues were derived exclusively from bridge testing.
Of the
$423,428 in research and development costs for the nine months ended September
30, 2008, $237,530 was incurred in salaries to our in-house engineering staff
which included an officer and director, $146,998 was paid to outside consultants
and for related expense reimbursements, and we valued the issuance of 150,000
shares of our common stock that were issued to various consultants at
$34,500. Of the $423,428 in research and development costs, $4,400 was
compensation expense recognized on the granting of options to our staff to
purchase a total of 400,000 shares of our common stock at a price per share of
$0.011.
Of the
$3,533,343 in research and development costs for the nine months ended September
30, 2007, $131,221 was incurred in salaries to our in-house engineering staff
which included an officer and director, $257,022 was paid to outside consultants
and for related expense reimbursements, and we valued the issuance of 2,116,000
shares of our common stock that were issued to various consultants at
$3,145,100.
General
and administrative expenses were $26,619,102 and $82,608,673, respectively, for
the nine months ended September 30, 2008 and 2007. The major expenses
incurred during each of the quarters were:
|
|
Nine
Months
Ended
September
30, 2008
|
|
|
Nine
Months
Ended
September
30, 2007
|
|
Consulting
services |
|
$ |
4,999,837 |
|
|
$ |
16,506,521 |
|
Officers’
salaries |
|
|
351,002 |
|
|
|
207,916 |
|
Officer’s
stock based compensation |
|
|
19,887,533 |
|
|
|
45,000,000 |
|
Office
salaries |
|
|
108,100 |
|
|
|
66,756 |
|
Office
expense |
|
|
63,167 |
|
|
|
66,480 |
|
Professional
fees |
|
|
680,927 |
|
|
|
856,463 |
|
Rent |
|
|
24,648 |
|
|
|
23,004 |
|
Marketing |
|
|
182,474 |
|
|
|
335,706 |
|
Impairment
loss |
|
|
- |
|
|
|
19,294,875 |
|
Payroll
taxes |
|
|
38,395 |
|
|
|
44,717 |
|
Travel |
|
|
82,173 |
|
|
|
104,659 |
|
Insurance |
|
|
51,997 |
|
|
|
30,208 |
|
Telephone |
|
|
16,696 |
|
|
|
19,740 |
|
Of the
$4,999,837 in consulting expense for the nine months ended September 30, 2008,
$3,586,240 was related to the issuance of 11,099,167 shares of common
stock. In addition, in exchange for the payment of $1,100,000 in
consulting fees by holders of convertible debt, we charged $1,100,000 in
consulting fees through an increase in convertible debt of the same
amount. Of the $16,506,521 in consulting expense for the nine months
ended September 30, 2007, $13,288,767 was related to the issuance of 8,650,424
shares of common stock. Of the $$856,463 in professional
fees for the nine months ended September 30, 2007, $655,300 was related to
the issuance of 1,800,000 shares of common stock.
Other
Income and Expenses and Net Loss
Our gain
on modification of convertible debt, modification of research and development
sponsorship agreement, loss on subscription receivables, interest expense,
other-than-temporary impairment of marketable securities, change in fair value
of derivative and warrant liabilities, loss on settlement of lawsuits, and net
loss for the nine months ended September 30, 2008 as compared to the nine months
ended September 30, 2007 are as follows:
|
|
Nine
Months Ended
September
30, 2008
|
|
|
Nine
Months Ended
September
30, 2007
|
|
|
Percentage
Change
|
|
Interest
expense |
|
$ |
(1,808,697 |
) |
|
$ |
(2,014,161 |
) |
|
|
(10.20 |
)% |
Loss
on modification of Convertible debt |
|
$ |
(964,730 |
) |
|
$ |
- |
|
|
|
-0- |
|
Net
unrealized and realized loss of marketable securities |
|
$ |
- |
|
|
$ |
(10,866,553 |
) |
|
|
-0- |
|
Change
in fair value of derivative and warrant liabilities |
|
$ |
10,431,555 |
|
|
$ |
14,505,323 |
|
|
|
(28,08 |
)% |
Interest
income |
|
$ |
15,879 |
|
|
$ |
35,270 |
|
|
|
(54.98 |
)% |
Provision
for income taxes |
|
|
(800 |
) |
|
|
(800 |
) |
|
|
0 |
% |
Net
loss |
|
$ |
(19,338,972 |
) |
|
$ |
(84,336,192 |
) |
|
|
77.07 |
% |
Our
interest expense includes amortization of debt discounts totaling $1,497,618
during the nine months ended September 30, 2008 and $1,765,110 during the nine
months ended September 30, 2007. The change in fair value of derivative
and warrant liabilities represents the change in derivative values related to
warrants and convertible debt with Palisades Capital, LLC and Golden Gate
Investors, Inc.
Results
of Operations for the Year Ended December 31, 2007 as Compared to the Year Ended
December 31, 2006 (audited)
Introduction
In 2007,
we had revenues from bridge testing. Our revenues for 2007 totaled
$201,917. We continued to fund the majority of our operations through the
issuance of our stock, resulting in large expenses in the areas of research and
development and consulting. The amount of cash used in our operations was
approximately $2,664,630 in 2007 compared to approximately $1,779,256 in
2006. We anticipate that we will continue to fund a substantial portion of
our operations through the sale of our securities until such time as we can
begin to generate substantial revenue from the sale of our products, and we do
not have an estimate of when such revenues will begin.
Revenues and Loss from
Operations
Our
revenue, research and development costs, general and administrative expenses,
and loss from operations for the year ended December 31, 2007 as compared to the
year ended December 31, 2006 are as follows:
|
|
Year
Ended
December
31,
2007
|
|
|
Year
Ended
December
31,
2006
|
|
|
Percentage
Change
|
|
Revenue
|
|
$ |
201,917 |
|
|
$ |
39,446 |
|
|
|
411.89 |
% |
Research
and development costs
|
|
|
3,701,966 |
|
|
|
902,446 |
|
|
|
310.21 |
% |
General
and administrative expenses
|
|
|
98,557,943 |
|
|
|
138,892,926 |
|
|
|
(29.04 |
)% |
Loss
from Operations
|
|
$ |
(73,396,581 |
) |
|
$ |
(177,884,101 |
) |
|
|
(58.74 |
)% |
Our
revenues for both 2007 and 2006 were derived exclusively from bridge
testing.
Of the
$3,701,966 in research and development costs for 2007, $197,005 was incurred in
salaries to our in-house engineering staff which included an officer and
director, $359,861 was paid to outside consultants and for related expense
reimbursements, and we valued the issuance of 2,116,000 shares of our common
stock that were issued to various consultants at $3,145,100. Of the
$1,013,969 in research and development costs for 2006, $111,523 was incurred in
salaries to our in-house engineering staff which included an officer and
director, $ 271,279 was paid to outside consultants and for related expense
reimbursements, and we valued the issuance of 36,028 shares of our common stock
that were issued to various consultants at $631,167.
General
and administrative expenses were $98,557,943 and $138,781,403, respectively, for
the years ended December 31, 2007 and 2006. The major expenses incurred
during each of the years were:
|
|
Year
Ended
December
31,
2007
|
|
|
Year
Ended
December
31,
2006
|
|
Consulting
services
|
|
$ |
16,855,747 |
|
|
$ |
125,332,072 |
|
Officer’s
salary
|
|
|
284,916 |
|
|
|
211,574 |
|
Officer’s
stock based compensation
|
|
|
60,048,000 |
|
|
|
6,575,342 |
|
Secretarial
salaries
|
|
|
132,754 |
|
|
|
114,561 |
|
Professional
Fees
|
|
|
1,053,280 |
|
|
|
974,704 |
|
Office
expense
|
|
|
97,459 |
|
|
|
52,855 |
|
Rent
|
|
|
139,173 |
|
|
|
28,176 |
|
Impairment
loss
|
|
|
19,294,875 |
|
|
|
1,913,445 |
|
Payroll
taxes
|
|
|
42,334 |
|
|
|
28,255 |
|
Telephone
|
|
|
27,929 |
|
|
|
17,375 |
|
Of the
$16,855,747 in consulting expense for the year ended December 31, 2007,
$12,394,888 was related to the issuance of 8,926,724 shares of common
stock. In addition, we charged $1,100,000 in consulting fees through
an increase in convertible debt of $1,100,000 and charged $2,845,000 to
consulting in connection with the acquisition of shares of Rocket City
Automotive. Of the $125,332,072 in consulting expense for the year ended
December 31, 2006, $124,543,689 was related to the issuance of 35,021,248 shares
of common stock.
Other Income and Expenses
and Net Loss
Our gain
on modification of convertible debt, modification of research and development
sponsorship agreement, loss on subscription receivables, interest expense,
other-than-temporary impairment of marketable securities, change in fair value
of derivative and warrant liabilities, loss on settlement of lawsuits, and net
loss for the year ended December 31, 2007 as compared to the year ended December
31, 2006 are as follows:
|
|
Year
Ended
December
31,
2007
|
|
|
Year
Ended
December
31,
2006
|
|
|
Percentage
Change
|
|
Gain
on modification of convertible debt
|
|
$ |
-0- |
|
|
$ |
1,033,479 |
|
|
|
(100 |
)% |
Interest
expense
|
|
|
(2,374,032 |
) |
|
|
(1,625,592 |
) |
|
|
46.04 |
% |
Net
unrealized and realized loss of marketable securities
|
|
|
(3,986,553 |
) |
|
|
(3,798,516 |
) |
|
|
4.95 |
% |
Change
in fair value of derivative and warrant liabilities
|
|
|
34,962,617 |
|
|
|
(33,780,874 |
) |
|
|
(196.5 |
)% |
Interest
income
|
|
|
60,179 |
|
|
|
37,120 |
|
|
|
62.12 |
% |
Other
|
|
|
-0- |
|
|
|
7,008 |
|
|
|
(100 |
)% |
Provision
for income taxes
|
|
|
(800 |
) |
|
|
(800 |
) |
|
|
|
|
Net
loss
|
|
$ |
(73,396,581 |
) |
|
$ |
(177,884,101 |
) |
|
|
(58.74 |
)% |
Our loss
of the gain on modification of convertible debt of $1,033,479 from 2006 is
related to our modification of the Palisades debt and removal of associated
derivative liability. Our interest expense includes amortization of
debt discounts totaling $2,041,213 in 2007 and $968,716 in 2006. The
change in fair value of derivative and warrant liabilities represents the change
in derivative values related to warrants and convertible debt with Palisades and
Golden Gate.
Liquidity
and Capital Resources
Introduction
During
the nine months ended September 30, 2008, as with the nine months ended
September 30, 2007, we did not generate positive cash flow. As a result,
we funded our operations through the private sale of equity and debt securities,
the issuance of our securities in exchange for services, and loans.
Our cash,
investments in marketable securities held for trading, investments in marketable
securities available for sale, accounts receivable, prepaid services, prepaid
expenses and other current assets, total current assets, total assets, total
current liabilities, and total liabilities as of September 30, 2008, as compared
to September 30, 2007, were as follows:
|
|
September
30,
2008
|
|
|
September
30,
2007
|
|
Cash |
|
$ |
441,076 |
|
|
$ |
987,284 |
|
Marketing
securities |
|
|
|
|
|
|
|
|
- trading |
|
$ |
- |
|
|
$ |
453,181 |
|
Marketing
securities |
|
|
|
|
|
|
|
|
- available for sale |
|
$ |
- |
|
|
$ |
120,000 |
|
Investment
in certificates of deposit |
|
$ |
- |
|
|
$ |
1,107,681 |
|
Accounts
receivable |
|
$ |
15,620 |
|
|
$ |
- |
|
Inventories |
|
$ |
156,054 |
|
|
$ |
- |
|
Prepaid
expenses and other |
|
$ |
70,423 |
|
|
$ |
204,501 |
|
Total
current assets |
|
$ |
683,173 |
|
|
$ |
2,872,647 |
|
Total
assets |
|
$ |
1,128,852 |
|
|
$ |
2,928,147 |
|
Total
current liabilities |
|
$ |
965,775 |
|
|
$ |
524,057 |
|
Total
liabilities |
|
$ |
6,737,797 |
|
|
$ |
34,171,450 |
|
Cash
Requirements
For the
nine months ended September 30, 2008, our net cash used in operations was
$(2,381,825) compared to $(2,450,964) for the nine months ended September 30,
2007.
Negative
operating cash flows during the nine months ended September 30, 2008 were
primarily created by a net loss from operations of $(19,338,972), offset by the
issuance of stock for services of $4,729,541, amortization of discount on
convertible debentures of $1,497,617 and an increase in officer stock based
compensation of $19,885,333. There was also a decrease in the fair value
of derivative and warrant liabilities of $(10,431,555), accrued interest on debt
of $272,077, net decrease in other assets of $19,961 and net decrease in other
liabilities of $19,443.
Negative
operating cash flows during the nine months ended September 30, 2007 were
primarily created by a net loss from operations of $(84,336,192), offset by
impairment losses of $19,294,877 incurred in connection with the acquisition of
a subsidiary, the issuance of stock for services of $19,519,168, amortization of
discount on convertible debentures of $1,765,110, a decrease in the fair value
of derivative and warrant liabilities of $(14,505,323), an increase in accounts
payable and accrued expenses of $(14,942), an increase in officer stock based
compensation of $45,000,000 and a net increase in other assets of
$(40,215). There was also a decrease in the fair value of derivative
and warrant liabilities of $14,505,323. Because of our need for cash to
fund our continuing research and development, we do not have an opinion as to
how indicative these results will be of future results.
Sources and Uses of
Cash
Net cash
provided by (used in) investing activities for the nine months ended September
30, 2008 and 2007 were $1,282,833 and $(865,333), respectively. For the
nine months ended September 30, 2008 and 2007, the net cash came primarily from
the sale of securities and maturities of other investments in the amount of
$1,865,000 and $537,174, respectively, offset by the amount for purchase of
securities of $(565,000) and $(1,952,038), respectively. Net cash from
investment activities during the quarter ended September 30, 2008 and 2007 were
further decreased by $17,167 and $50,469, respectively, for amounts we paid in
the purchase of property and equipment.
Net cash
provided by financing activities for the nine months ended September 30, 2008
and 2007, was $730,358 and $4,174,285, respectively. For the nine months
ended September 30, 2008, the net cash used pertained to the purchase of 207,000
shares of our common stock still
held in
treasury totaling $3,266 and an increase in the amount of indebtedness of
$1,115,000. In addition, during the nine month ended September 30,
2008, the Company received $18,624 through the issuance of 77,600 shares of its
common stock. For the nine months ended September 30, 2007, the net
cash came primarily from the sale of common stock and warrants of $4,079,935 and
proceeds from convertible debentures and other notes payable of
$200,000.
We are
not generating sufficient cash flow from operations to fund growth. We
cannot predict when we will begin to generate revenue from the sale of our
products, and until that time, we will need to raise additional capital through
the sale of our securities. If we are unsuccessful in raising the required
capital, we may have to curtail operations.
Critical
Accounting Policies
The
discussion and analysis of our financial condition and results of operations are
based upon our consolidated financial statements, which have been prepared in
accordance with accounting principles generally accepted in the United States of
America. The preparation of these financial statements requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses. In consultation with our Board of Directors, we
have identified the following accounting policies that we believe are key to an
understanding of our financial statements. These are important accounting
policies that require management’s most difficult, subjective
judgments.
The first
critical accounting policy relates to revenue recognition. Income from our
research is recognized at the time services are rendered and
billed.
The
second critical accounting policy relates to research and development
expense. Costs incurred in the development of our products are expensed as
incurred.
The third
critical accounting policy relates to the valuation of non-monetary
consideration issued for services rendered. We value all services rendered in
exchange for our common stock at the quoted price of the shares issued at date
of issuance or at the fair value of the services rendered, which ever is more
readily determinable. All other services provided in exchange for other
non-monetary consideration is valued at either the fair value of the services
received or the fair value of the consideration relinquished, whichever is more
readily determinable.
Our
accounting policy for equity instruments issued to consultants and vendors in
exchange for goods and services follows the provisions of EITF 96-18, Accounting for Equity Instruments
That are Issued to Other Than Employees for Acquiring, or in Conjunction with
Selling, Goods or Services ” and EITF 00-18, Accounting Recognition for Certain
Transactions Involving Equity Instruments Granted to Other Than
Employees.” The measurement date for the fair value of the equity
instruments issued is determined at the earlier of (i) the date at which a
commitment for performance by the consultant or vendor is reached or (ii) the
date at which the consultant or vendor’s performance is complete. In the
case of equity instruments issued to consultants, the fair value of the equity
instrument is recognized over the term of the consulting
agreement. In accordance to EITF 00-18, an asset acquired in exchange
for the issuance of fully vested, nonforfeitable equity instruments should not
be presented or classified as an offset to equity on
the
grantor’s balance sheet once the equity instrument is granted for accounting
purposes. Accordingly, we record the fair value of nonforfeitable
common stock issued for future consulting services as prepaid services in our
consolidated balance sheet.
The
fourth critical accounting policy is our accounting for conventional convertible
debt. When the convertible feature of the conventional convertible debt
provides for a rate of conversion that is below market value, this feature is
characterized as a beneficial conversion feature (BCF”). We record a BCF
as a debt discount pursuant to EITF Issue No. 98-5 (EITF 98-05), Accounting for Convertible
Securities with Beneficial Conversion Features or Contingency Adjustable
Conversion Ratio,” and EITF Issue No. 00-27, Application of EITF Issue No. 98-5
to Certain Convertible Instrument(s).” In those
circumstances, the convertible debt will be recorded net of the discount related
to the BCF. We amortize the discount to interest expense over the life of
the debt using the effective interest method.
The fifth
critical account policy relates to the accounting for non-conventional
convertible debt and the related stock purchase warrants. In the case of
non-conventional convertible debt, we bifurcate our embedded derivative
instruments and record them under the provisions of SFAS No. 133, Accounting for Derivative
Instruments and Hedging Activities,” as amended, and
EITF Issue No. 00-19,
Accounting for Derivative Financial Instruments Indexed to, and Potentially
Settled in, a Company’s Own Stock.” These embedded derivatives
include the conversion feature, liquidated damages related to registration
rights and default provisions. The accounting treatment of derivative
financial instruments requires that we record the derivatives and related
warrants at their fair values as of the inception date of the agreement and at
fair value as of each subsequent balance sheet date. In addition, under
the provisions of EITF Issue No. 00-19, as a result of entering into the
non-conventional convertible debenture, we are required to value and classify
all other non-employee stock options and warrants as derivative liabilities at
that date and mark them to market at each reporting date thereafter. Any
change in fair value will be recorded as non-operating, non-cash income or
expense at each reporting date. If the fair value of the derivatives is
higher at the subsequent balance sheet date, we will record a non-operating,
non-cash charge. If the fair value of the derivatives is lower at the
subsequent balance sheet date, we will record non-operating, non-cash
income. We value our derivatives primarily using the Black-Scholes Option
Pricing Model. The derivatives are classified as long-term
liabilities.
The sixth
critical accounting policy relates to the recording of marketable securities
held for trading and available-for-sale. Marketable securities purchased
with the intent of selling them in the near term are classified as trading
securities. Trading securities are initially recorded at cost and are
adjusted to their fair value, with the change in fair value during the period
included in earnings as unrealized gains or losses. Realized gains or
losses on dispositions are based upon the net proceeds and the adjusted book
value of the securities sold, using the specific identification method, and are
recorded as realized gains or losses in the consolidated statements of
operations. Marketable securities that are not classified as trading
securities are classified as available-for-sale securities.
Available-for-sale securities are initially recorded at cost.
Available-for-sale securities with quoted market prices are adjusted to their
fair value, subject to an impairment analysis (see below). Any change in
fair value during the period is excluded from earnings and recorded, net of tax,
as a component of accumulated other comprehensive income (loss). Any
decline in value of available-for-sale securities below cost that is considered
to be
other
than temporary is recorded as a reduction of the cost basis of the security and
is included in the statement of operations as a write down of the market value
(see below).
The
seventh critical accounting policy is our accounting for the fair market value
of non-marketable securities we have acquired. Non-marketable securities
are originally recorded at cost. In the case of non-marketable
securities we acquired with our common stock, we value the securities at a
significant discount to the stated per share cost based upon our historical
experience with similar transactions as to the amount ultimately realized from
the sale of the shares. Such investments are reduced when we have
indications that a permanent decline in value has occurred. At such time
as quoted market prices become available, the net cost basis of these securities
will be reclassified to the appropriate category of marketable securities.
Until that time, the securities will be recorded at their net cost basis,
subject to an impairment analysis (see below).
In
accordance with the guidance of EITF 03-1, The Meaning of Other-Than-Temporary
Impairment and Its Application to Certain Investments, we assess any
decline in value of available-for-sale securities and non-marketable securities
below cost as to whether such decline is other than temporary. If a
decline is determined to be other than temporary, the decline is recorded as a
reduction of the cost basis of the security and is included in the statement of
operations as an impairment write down of the investment.
Effective
September 11, 2007, KMJ/Corbin and Company, LLP (“KMJ”) resigned as our
independent registered public accounting firm for the fiscal year ended December
31, 2007.
We
engaged KMJ on January 21, 2005. For the last two fiscal years, KMJ’s
reports on our financial statements did not contain an adverse opinion or a
disclaimer of opinion, nor were the reports qualified or modified as to audit
scope, or accounting principles, but they were modified as to uncertainty about
our ability to continue as a going concern. For the last two fiscal
years and any subsequent interim period preceding the dismissal, there were no
disagreements with KMJ on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure which, if not
resolved to the satisfaction of KMJ would have caused KMJ to make reference to
the matter in their reports.
We
engaged Weinberg & Company, P.A. (hereinafter “Weinberg”) as our principal
accountants to audit our financial statements effective as of September 11,
2007. Effective November 5, 2007, we dismissed Weinberg as our independent
registered public accounting firm for the fiscal year ended December 31,
2007. Weinberg never issued a report on our financial
statements. During their engagement, there were no disagreements with
Weinberg on any matter of accounting principles or practices, financial
statement disclosure, or auditing scope or procedure which, if not resolved to
the satisfaction of Weinberg would have caused Weinberg to make reference to the
matter in their reports.
We
engaged Kabani & Company, Inc. (hereinafter “Kabani”) as our principal
accountants to audit our financial statements effective as of November 5, 2007.
Effective March 13, 2008, we dismissed Kabani as our independent
registered public accounting firm for the fiscal year ended December 31,
2008. Kabani’s services were limited to a review of our Quarterly
Report on Form 10-QSB for the quarter ended September 30,
2007. During their engagement, there were no disagreements with
Kabani on any matter of accounting principles or practices, financial statement
disclosure, or auditing scope or procedure which, if not resolved to the
satisfaction of Kabani would have caused Kabani to make reference to the matter
in their reports.
We
engaged Gruber & Co. LLC (hereinafter “Gruber”) as the principal accountants
to audit our financial statements effective as of March 13, 2008. We,
during our most recent fiscal year and any subsequent interim period to the date
hereof, did not have discussions nor have we consulted with Gruber regarding the
following: (i) the application of accounting principles to a specified
transaction, either completed or proposed or the type of audit opinion to be
rendered on the our financial statements, and neither a written report was
provided to us nor oral advice was provided that Gruber concluded was an
important factor considered by us in reaching a decision as to the accounting,
auditing or financial reporting issue; or (ii) any matters that were the subject
of a “disagreement,” as that term is defined in Item 304(a)(1)(iv) of Regulation
S-B and the related instructions to Item 304 of Regulation S-B, or a reportable
event.
Development
of Business
We were
formed as a Delaware corporation on March 4, 1997. We are the successor to
the business of Material Technology, Inc., a Delaware corporation, also doing
business as Tensiodyne Scientific, Inc. Material Technology, Inc. was the
successor to the business of Tensiodyne Corporation that began developing the
Fatigue Fuse in 1983. Our two predecessors, Tensiodyne Corporation and
Material Technology, Inc. were engaged in developing and testing our Fatigue
Fuse and, beginning in 1993, developing our Electrochemical Fatigue
Sensor. We changed our name from Material Technologies, Inc. to
Matech Corp. on October 3, 2008.
Our
Business
Over the
last several years, we were engaged in research and development of metal fatigue
detection, measurement, and monitoring technologies. We have now developed
several monitoring devices for metal fatigue detection and measurement. We
are currently marketing our technology.
Our
efforts have been dedicated to developing devices and systems that indicate the
true status of fatigue damage in a metal component. We have developed two
products. The first is a small, simple device that continuously integrates
the effect of fatigue loading in a structural member, called a Fatigue
Fuse. The second is an instrument that detects very small growing fatigue
cracks in metals, the Electrochemical Fatigue Sensor. The
Electrochemical Fatigue Sensor has demonstrated in the laboratory that it can
detect cracks as small as 10 microns (0.0004 inches), which we believe is
smaller than any other practical crack detection technology. The
Company holds the patents on the Fatigue Fuse and the license on the technology
on the Electrochemical Fatigue Sensor from the University of Pennsylvania and
licenses both of those technologies to us.
We have
completed the technology to the point where we are now performing real world
bridge inspections.
The
Federal Highway Administration (FHA) has signed a $347,500 contract with us to
purchase equipment and training as part of their Steel Bridge Testing
Program. They will use our EFS system in the laboratory and on actual
bridges to find growing fatigue cracks. Following the completion of
this program, the FHA will recommend technologies for use on bridges for
specific bridge problems.
Our
on-call contract with the Pennsylvania Department of Transportation (PennDOT) is
continuing to produce good results. We have used the EFS on 12
bridges in Pennsylvania so far, totaling over $100,000. We anticipate
further work orders to be issued for the next inspection season. We
have also received interest from several inspection companies in Pennsylvania to
purchase EFS equipment, as well as training and licensing, in order to execute
these further work orders, with licensing fees payable to us for each bridge
inspected. One such company has already been trained at their cost to
help us execute on-call contracts in 2008.
We
completed a contract with Massachusetts (MassHighway) for $24,290. We
then met with MassHighway representatives who hired us to conduct additional
bridge inspections during 2008.
New York
State contracted with us to provide EFS inspection services on a high profile
fracture critical bridge for $9,630. As a result of this initial
inspection for the New York State Department of Transportation, we will be
performing a follow up inspection. Additionally, they are evaluating
purchase of equipment, training for their engineers, and licensing in
2008.
We have
completed an inspection of a fracture critical bridge in West Sacramento,
California, and are also in the process of analyzing and reporting the
results. At the same time we have met with several high-ranking state
and national officials in California, with more meetings planned, all discussing
the use of EFS across the state.
We have
also formed a strategic alignment with a California-based independent testing
laboratory called Smith Emery Company. Smith Emery Company is over
100 years old and has over 400 employees in California as well as an office in
China. They perform weld testing, building façade testing, and
metallurgical failure analysis. Engineers and technicians have
already been trained at their cost to execute contracts in the western U.S.
region.
We have
signed a contract with the Canadian National Railway to inspect a bridge in
Wisconsin. The Canadian National Railway owns a number of bridges in
the United States.
We have
completed and sent PennDOT a report on the nine bridges we inspected in
Pennsylvania. We hope to meet with PennDOT in the near future to
discuss the use of EFS on their remaining steel bridges.
We have
been invited by the U.S. Army Corps of Engineers to present at the U.S.
Secretary of Defense’s office on May 1 and 2, 2008. The U.S. Army
Corps of Engineers owns all of the bridges over U.S. federal
waterways.
We have
scheduled inspections in 2008 for the following entities so far:
|
·
|
Virginia
Department of Transportation
|
|
·
|
Canadian
National Railway
|
|
·
|
Alabama
Department of Transportation
|
|
·
|
New
York Department of Transportation
|
We have
been hired to perform inspections with the following entities which have not yet
been scheduled:
|
·
|
New
Jersey Department of Transportation
|
Our
Technologies
The Fatigue
Fuse
The
Fatigue Fuse is designed to be affixed to a structure to give warnings at
pre-selected percentages of the fatigue life that have been used up (i.e., how
close to failure the structure has progressed). It warns against a
condition of widespread generalized cracking due to fatigue.
The
Fatigue Fuse is a thin piece of metal similar to the material being
monitored. It consists of a series of parallel metal strips connected to a
common base, much as fingers are attached to a hand. Each “finger” has a
different geometric pattern, called “notches,” defining its boundaries.
Each finger incorporates an application-specific notch near the base. By
applying the laws of physics and fracture mechanics to determine the geometric
contour of each notch, the fatigue life of each finger is finite and
predictable. When the fatigue life of a finger (Fuse) is reached, the Fuse
breaks.
By
implementing different geometry for each finger notch in the array, different
increments of fatigue life are observable. Typically, notches will be
designed to facilitate observing increments of fatigue life of 10% to
20%. By mechanically attaching or bonding these devices to
different areas of the structural member of concern, the Fuse undergoes the same
fatigue history (strain cycles) as the structural member. Therefore,
breakage of a Fuse indicates that an increment of fatigue life has been reached
for the structural member. The notch and the size and shape of the notch
concentrate energy on each finger. The Fuse is intimately attached to the
structural member of interest. Therefore, the Fuse experiences the same
strain and wear history as the member. Methods are available for remote
indication of Fuse fracturing.
In a new
structure, we generally assume there is no fatigue and can thus design the
Fatigue Fuse for 100% of its life potential. But in an existing structure,
one that has experienced loading and wear, we must determine the fatigue status
of that structural member so we can design the Fatigue Fuse to monitor the
remaining fatigue life potential.
We
believe that the Fatigue Fuse is of value in monitoring aircraft, ships,
bridges, conveyor systems, mining equipment, cranes, etc. Little special
training is needed to qualify individuals to report any broken segments of the
Fatigue Fuse to the appropriate engineering authority for necessary
action. The success of the device is contingent upon our successful
marketing of the Fatigue Fuse, and no assurance can be given that we will be
able to overcome the obstacles relating to introducing a new product to the
market. To implement our ability to produce and market the Fatigue Fuse,
we need substantial additional capital and no assurance can be given that this
needed capital will be available.
The Electrochemical Fatigue
Sensor (EFS”)
The EFS
is a device that employs the principle of electrochemical/mechanical interaction
of metals under repeated loading to find growing cracks. It is an
instrument that detects very small
cracks
and has the potential to determine crack growth rates. The Electrochemical
Fatigue Sensor has demonstrated in the laboratory that it can detect cracks as
small as 10 microns (0.0004 inches), which we believe is smaller than any other
practical technology. We believe that nothing comparable to this
instrument currently exists in materials technology. We have inspected
approximately 33 bridges to date using this technology.
The EFS
functions by treating the location of interest (the target) associated with the
structural member as an electrode of an electrochemical cell (similar to a
battery). By imposing a constant voltage-equivalent circuit as the control
mechanism for the electrochemical reaction at the target surface, current flows
as a function of stress action. The EFS is always a dynamic process;
therefore stress action is required, e.g., to measure a bridge structural member
it is necessary that cyclic loads be imposed, such as normal traffic on the
bridge would do. The results are a specific set of current waveforms and
amplitudes that characterize and indicate fatigue damage i.e., growing fatigue
cracks.
Status
of our Technologies
Currently,
our primary focus is on the commercialization of the EFS.
Status of the
EFS
Within
the past twelve months, we have successfully used EFS on 18 highway and railroad
bridges. We are now actively marketing the EFS for
bridges.
Status of the Fatigue
Fuse
To date,
certain organizations have included our Fatigue Fuse in test programs. We
have already completed the tests for welded steel civil bridge members conducted
at the University of Rhode Island. In 1996, Westland Helicopter, a British
firm, tested the Fatigue Fuse on helicopters. That test was successful
with the legs of the Fatigue Fuses failing in sequence as predicted. At the
present time, we are applying Fatigue Fuses to several portable aluminum bridges
for the U.S. Army.
The
Fatigue Fuse has been at this stage for the past several years as we have not
had the necessary financial resources to finalize our development and commence
marketing. At the present time we have elected to defer future development
of the Fatigue Fuse and apply our resources to pursue the EFS
technology.
Commercial
Markets for our Products and Technologies
Our
technology is applicable to many market sectors such as bridges and aerospace as
well as ships, cranes, railways, power plants, nuclear facilities, chemical
plants, mining equipment, piping systems, and heavy iron.
Application
of Our Technologies for Bridges
Our EFS and Fatigue Fuse
products primarily address the detection of fatigue in structures such as
bridges. In the United States alone, there are more than 610,000 bridges
of which over 260,000 are rated by the Federal Highway Administration as
requiring major repair, rehabilitation, or replacement. Our EFS and
Fatigue Fuse products can be effectively used as fatigue detection devices for
all metal bridges located within the United States. Our detection devices
also address maintenance problems associated with bridge
structures.
Although
there are normal business imperatives, the bridge market is essentially
macro-economically and government policy driven. In our opinion, only
technology can provide the solution. The need for increased spending
accelerates significantly each year as infrastructure ages. The Federal
government has mandated bridge repair and detection through the passage of the
Intermodal Surface Transportation and Efficiency Act in 1991 and again in the
$200 billion, 1998 Transportation Equity Act. We have completed several
contracts to install our fatigue detection products on bridge structures within
the United States, and are in negotiations for several others.
Our
Patent Protections
We have
the following patent protection on our technology through either ownership or
license as indicated:
Title
|
Patent
Number
|
Our
Status
|
Expiration
Date
|
Device
for Monitoring Fatigue Life
|
4,590,804
|
Owner
by assignment
|
12/31/2014
|
Method
of Making a Device for Monitoring Fatigue Life
|
4,639,997
|
Owner
by assignment
|
12/31/2015
|
Metal
Fatigue Detector
|
5,237,875
|
Owner
by assignment
|
12/31/2011
|
Device
for Monitoring the Fatigue Life of a Structural Member and a Method of
Making Same
|
5,319,982
|
Owner
by assignment
|
12/31/2012
|
Device
for Monitoring the Fatigue Life of a Structural Member and a Method of
Making Same
|
5,425,274
|
Owner
by assignment
|
12/31/2014
|
Methods
and Devices for Electrochemically Determining Metal Fatigue
Status
|
5,419,201
|
Licensee
|
12/31/2013
|
Methods
and Devices for Electrochemically Determining Metal
Fatigue
|
6,026,691
|
Licensee
|
12/31/2015
|
Our
Patents are Encumbered
The
patents described in the preceding section are pledged as collateral to secure
the repayment of loans extended to us or indebtedness that we currently
owe. On August 30, 1986, we entered into a funding agreement with the
Advanced Technology Center, whereby ATC paid $45,000 to us for the
purchase of a royalty of 3% of future gross sales and 6% of sublicensing
revenue. The royalty is limited to the $45,000 plus an 11% annual rate of
return. The payment of future royalties was secured by equipment we used
in the development of technology as specified in the funding agreement, however,
no lien against our equipment or our patents in favor of ATC vested until we
generated royalties from product sales.
On May 4,
1987, we entered into a funding agreement with ATC whereby ATC provided $63,775
to us for the purchase of a royalty of an additional 3% of future gross sales
and 6% of sublicensing revenue. The agreement was amended August 28, 1987,
and as amended, the royalty cannot exceed the lesser of (1) the amount of the
advance plus a 26% annual rate of return or, (2) total royalties earned for a
term of 17 years. As with our first agreement with ATC, no lien or
encumbrance against our assets, including our patents, vested in favor of ATC
until we generated royalties from product sales.
On
September 28, 2006, we entered into an agreement with Ben Franklin Technology,
the successor to ATC, to give Ben Franklin 3,334 shares of our common stock,
valued at $40,000, in exchange for a general release of the above
liabilities.
On May
27, 1994, we borrowed $25,000 from Sherman Baker, one of our shareholders.
We gave Mr. Baker a promissory note due May 31, 2002 and we pledged our patents
as collateral to secure the repayment of this note. As of December 31,
2007, there is a first priority security interest in our patents as collateral
for the repayment of the amounts we owe to Mr. Baker. As additional
consideration for this loan, we granted to Mr. Baker a 1% royalty interest in
the Fatigue Fuse and a 0.5% royalty interest in the Electrochemical Fatigue
Sensor. We are in default of the repayment terms of the note held by Mr.
Baker, and at December 31, 2007, we owe Mr. Baker $56,761 in principal and
accrued interest. Mr. Baker has not taken any action to foreclose his
interest in the collateral and we are in discussions with Mr. Baker, with the
expectation that we will cure any default in the note he holds and avoid any
foreclosure of his security interest held in our patents. We believe that
although we have not yet cured our defaults on the loans to Mr. Baker, our
current communications with him suggest that Mr. Baker does not have the present
intention of foreclosing on the patents as collateral or the pursuit of legal
action against us to collect the balance due under our note.
On July
31, 2008, we issued a $1,000,000 10% convertible debenture to Kreuzfeld
Ltd. Also on July 31, 2008, we entered into a Security Agreement with
Kreuzfeld Ltd. whereby we granted Kreuzfeld Ltd. a security interest in our
assets, including all of our patents. See "Description of Securities to be
Registered−Convertible
Debentures."
Distribution
of our Products
Subject
to available financing, we have and continue to exhibit the Electrochemical
Fatigue Sensor, and to a lesser extent the Fatigue Fuse, at various trade shows
and intend to also market our products directly to end users including certain
state regulatory agencies charged with overseeing bridge maintenance, companies
engaged in manufacturing and maintaining large ships and tankers, and the
military. Although we intend to undertake marketing, dependent on the
availability of funds, within and without the United States, no assurance can be
given that any such marketing activities will be implemented.
Competition
Other
technologies exist which identify cracks which may be the result of fatigue
damage. Single cracks larger than a minimum size can be found by
nondestructive inspection methods such as dye penetrant, radiography, eddy
current, acoustic emission, and ultrasonics. Tracking of load and strain
history, to subsequently estimate fatigue damage by computer processing, is
possible with recording instruments such as strain gauges and counting
accelerometers. These methods have been used for over 40 years and also
offer the advantage of having been accepted in the market, whereas our products
remain largely unproven. Companies marketing these alternate technologies
include Magnaflux Corporation, Kraut-Kramer-Branson, Dunegan-Endevco, and Micro
Measurements. These companies have more substantial assets, greater
experience, and more resources than us, including, but not limited to,
established distribution channels and an established customer base. The
familiarity and loyalty to these technologies may be difficult to
dislodge. Because we are still in the development stage, we are unable to
predict whether our technologies will be successfully developed and commercially
attractive in potential markets.
Employees
We have
six full-time employees. In addition, we retain consultants on an
independent contractor basis for specialized work.
Description
of Property
We lease
an office at 11661 San Vicente Blvd., Suite 707, Los Angeles, California, 90049.
The space consists of 830 square feet and will be adequate for our current
and foreseeable needs. The total rent is payable at $2,582 per month on a
month-to-month basis. Either party may cancel the lease on 30 days
notice.
Legal
Proceedings
Stephen
Beck
In July
2002, we settled a lawsuit related to a contract dispute with Mr. Stephen Beck.
In March 2006, Mr. Beck filed a lawsuit against us alleging breach of
contract related to the lawsuit settlement and sought monetary damages, plus the
issuance of shares of our common stock plus interest.
In
December 2006, we entered into a settlement and release agreement, as well as
irrevocable escrow instructions, to settle the lawsuit Mr. Beck filed in March
2006. As consideration under the settlement, we issued 5,000,000 shares of
our common stock to Mr. Beck, with the shares to be held by an escrow agent and
distributed to Mr. Beck monthly with a trading limit equal to 8% of the previous
month’s trading volume of our common stock, until Mr. Beck received a total of
$800,000. As Mr. Beck received proceeds from the sale of his shares into
the market and 7.5% (net of any expenses incurred by us) of any cash raised by
us from the sale of equity, we would reduce our guarantee by that
amount. We have paid a total of $285,182 to Mr. Beck in cash
as
part of
the settlement. Mr. Beck also had anti-dilution rights on those shares to
maintain his percentage ownership through September 27, 2008. We issued
another 5,000,000 shares to Mr. Beck to be held in escrow until the conditions
were met with respect to the anti-dilution shares. As of the date of this
prospectus, we have issued a total of 1,393,617 shares of common stock to Mr.
Beck pursuant to the anti-dilution provision in the settlement arrangement.
In or about February 2008, Mr. Beck reached the $800,000 guarantee from
the sale of our common stock and the cash received from us for 7.5% of the
capital we raised. Therefore, as of the date of this prospectus, we have
no further liability to Mr. Beck.
On
September 12, 2007, we filed a complaint for declaratory relief against Mr. Beck
in the Superior Court of the State of California, County of Los Angeles, Central
Judicial District, seeking a judicial determination as to the respective rights
and duties of us and Mr. Beck with respect to certain terms and conditions of
the settlement agreement and escrow instructions.
On
February 7, 2008, we filed a first amended complaint in our action against Mr.
Beck for declaratory relief which now also seeks to have the settlement
agreement and escrow instructions rescinded. On March 6, 2008, Mr. Beck
filed a cross-complaint against us and Robert M. Bernstein, our President and a
Director, for breach of contract, specific performance, declaratory relief,
conversion, intentional interference with contract (against Mr. Bernstein only)
and, in the alternative, equitable restitution. Trial is scheduled
for February 2, 2009.
Gem Advisors, Inc., GEM
Global Emerging Markets, and Global Emerging Markets of North America,
Inc.
On June
15, 2005, we filed a Complaint in the Los Angeles Superior Court, State of
California, case number BC336689, against Gem Advisors, Inc., GEM Global
Emerging Markets, and Global Emerging Markets of North America, Inc., seeking a
declaration regarding certain agreements we entered into with the parties.
We did not seek monetary damages. On November 16, 2005, Gem Advisors, Inc.
filed an Answer and Cross-Complaint, seeking approximately $1.9 million in
damages arising out of finders fees for certain transactions. On November
30, 2005, default judgments were entered against the other defendants who failed
to respond to our Complaint. In September 2006, this case was dismissed as
to all parties because the parties thought they could agree on the terms of a
written settlement agreement. However, the parties failed to reach a
settlement and no formal settlement agreement was ever executed.
On
November 30, 2007, Gem Advisors, Inc. filed a lawsuit
against us, Robert M. Bernstein, and Lawrence I. Washor (who
represented us in the lawsuit against Gem Advisors, Inc. filed on June
15, 2005), for breach of contract (settlement), breach of contract (for transfer
to Gem Advisors, Inc. of 585,000 shares we held in another company), breach of
covenant of good faith and fair dealing, and fraud and deceit – promise made
without intention to perform (the only cause of action asserted against Robert
M. Bernstein and Lawrence I. Washor). Gem Advisors, Inc. sought damages in
excess of $250,000. On April 10, 2008, the court dismissed Lawrence I. Washor
from the lawsuit. On October 9, 2008, we agreed to a settlement with
the plaintiffs that, in exchange for dismissal of the lawsuit, we will pay the
plaintiffs the total sum of $250,000 as follows: (1) $15,000 by November 30,
2008; (2) $5,000 per month each month thereafter; and (3) a percentage of any
net funds received for any equity or debt instrument sold, including any funds
received from Robert M. Bernstein from the sale of his stock, to reduce the
$250,000 Settlement amount, as follows: (i) 5% up to the first $2,000,000
received, (ii) 4% for amounts received between $2,000,001 to $4,000,000, and
(iii) 3% of all amounts received over $4,000,000.
Directors
and Executive Officers
The
following table sets forth the names, positions, and ages of our current
directors and executive officers. Our executive officers are appointed by
the Board of Directors. The directors serve one-year terms until their
successors are elected. The executive officers serve until their death,
resignation or removal by the Board of Directors. Unless described below,
there are no family relationships among any of the directors and officers, and
none of our officers or directors serves as a director of another reporting
issuer.
Name
|
Age
|
Position(s)
|
|
|
|
Robert
M. Bernstein
|
74
|
Chief
Executive Officer, President, Chief Financial Officer,
Director
Officer
and Chairman of the Board (1988)
|
Marybeth
Miceli Newton
|
31
|
Chief
Operating Officer
|
Joel
R. Freedman
|
47
|
Secretary
and Director
|
William
I. Berks
|
77
|
Vice
President and Director
|
Brent
Phares
|
36
|
Chief
Engineer
|
Robert M. Bernstein, President, CEO,
Chief Financial Officer, and Director. Mr. Bernstein received a
Bachelor of Science degree from the Wharton School of the University of
Pennsylvania in 1956. From August 1959 until his certification expired in
August 1972, he was a Certified Public Accountant licensed in Pennsylvania.
From 1961 to 1981, he was a consultant specializing in mergers,
acquisitions, and financing. From 1981 to 1986, Mr. Bernstein was Chairman
and Chief Executive Officer of Blue Jay Enterprises, Inc. of Philadelphia,
Pennsylvania, an oil and gas exploration company. In December 1985, Mr.
Bernstein formed a research and development partnership for our company, funding
approximately $750,000 for research on the Fatigue Fuse. In October 1988,
Mr. Bernstein became our President, CEO, and Chief Financial
Officer.
Joel R. Freedman, Secretary and
Director. From October 1989 and continuing through the present, Mr.
Freedmen has been our Secretary and a Director. From 1983 through 1999,
Mr. Freedmen was President of Genesis Advisors, Inc., an investment advisory
firm in Bala Cynwyd, Pennsylvania. From January 2000 through December
2002, Mr. Freedmen was a Senior Vice President of PMG Capital Corp., a
securities brokerage and investment advisory firm in West Conshohocken,
Pennsylvania. From December 2002 and continuing through the present, Mr.
Freedmen has been Senior Vice President of Wachovia Securities, LLC, a
securities brokerage and investment advisory firm in Conshohocken,
Pennsylvania.
William Berks, Vice President and
Director. Mr. Berks joined us as our Vice President and Director in
June 1997. Mr. Berks holds six patents and has over 30 years experience in
spacecraft mechanical systems engineering. Mr. Berks has a Bachelor of
Science in
Aeronautical Engineering and a Master of Science in Applied Mechanics from
Polytechnic Institute of New York, as well as a Master of Science in Industrial
Engineering from Stevens Institute of Technology. Prior to joining us, Mr.
Berks was with TRW Incorporated for 26 years
in a
variety of management positions, where his duties included flight hardware
fabrication and testing and where he was responsible for overseeing 350
employees.
Marybeth Miceli, Chief Operating
Officer. Ms. Miceli has over 12 years experience in nondestructive
evaluation and testing of civil infrastructure. Ms. Miceli joined us as
our Chief Operating Officer in July 2007. From June 2005 through August
2007, Ms. Miceli was Director of Marketing for Sam Schwartz, LLC, Engineering
and Planning Consultants, New York, in the areas of infrastructure management,
non-destructive testing, and fatigue testing. From January 2001 through
May 2005, Ms. Miceli was with Lucius Pitkin, Inc., Engineering Consultants,
where Ms. Miceli’s responsibilities included Quality Assurance Manager, and
Assistant Radiation Safety Officer. Among Ms. Miceli’s duties was the
supervision and performance of failure analysis investigations, fatigue testing
investigations, and interfacing with government agencies on testing,
regulations, and safety. Ms. Miceli is currently in the first year of a
three year term serving as a director of the American Society of Non-destructive
Testing, and Chairman in 2003 of the Metropolitan New York Chapter. Ms.
Miceli is a graduate of Johns Hopkins University and has a Master of
Science in Materials Science and Engineering, from Virginia Polytechnic
Institute. Ms. Miceli is a member of the American Society of Metals and
has published several papers on non-destructive testing of bridge components and
other related subjects.
Brent M. Phares, Chief
Engineer. Dr. Phares has over 15 years of management, inspection,
research, and testing experience related to bridge structures. From
October 2001 and continuing through the present, Dr. Phares has been the
Associate Director for Bridges and Structures at
Iowa State University. In this position, Dr. Phares is
responsible for the development and deployment of innovative bridge evaluation
and techniques and for the development of applications for innovative materials
in bridge engineering. From June 2001 through October 2004, Dr. Phares
served as President and CEO of MGPS, Inc., an engineering firm specializing in
the evaluation of civil infrastructure based on innovative sensors and
monitoring strategies. Dr. Phares has served as a consulting Research
Engineer at the Federal Highway Administration’s
Nondestructive Evaluation Validation Center where he led the
execution of several validation and developmental studies. Dr. Phares is a
registered professional engineer and serves as a voting member of many national
and international technical committees. Dr. Phares joined us in June
2007.
Director
Independence; Committees of the Board of Directors; Shareholder
Communications
We are
not required to have independent directors and, accordingly, have not made any
determination whether any of our directors are independent using any
standard. We are not required to have and do not have a nominating
committee, audit committee, compensation committee, or any other committee of
our board of directors. We do not have a formal process for security
holders to send communications to our board of directors, however, security
holders may send communications to our contact information listed in all of our
filings with the Securities and Exchange and Commission as well as to the
contact information listed on our website.
Terms
of Office
Our
directors are appointed for a one year term to hold office until the next annual
general meeting of the holders of our Common Stock or until removed from office
in accordance with our by-laws. Our officers are appointed by our board of
directors and hold office until removed by our board of directors.
Summary
Compensation Table
Set forth
below is a summary of compensation for our principal executive officer and our
two most highly compensated officers other than our principal executive officer
(collectively, the “named executive officers”) for our last two fiscal years.
There have been no annuity, pension or retirement benefits ever paid to our
officers, directors or employees.
With the
exception of reimbursement of expenses incurred by our named executive officers
during the scope of their employment and unless expressly stated otherwise in a
footnote below, none of the named executive officers received other
compensation, perquisites and/or personal benefits in excess of
$10,000.
Name
and Principal Position
|
|
Year
|
|
|
Salary
($)
|
|
|
Bonus
($)
|
|
|
Stock
Awards ($)
|
|
|
Option
Awards ($)
|
|
|
Non-equity
Incentive Plan Compen-sation ($)
|
|
|
All
Other Compen-sation ($)
|
|
|
Total
($)
|
|
Robert
M. Bernstein, CEO, President, CFO
|
|
2007
|
|
|
$ |
250,000 |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
250,000 |
|
|
|
2006
|
|
|
$ |
206,500 |
|
|
$ |
-0- |
|
|
$ |
180,000,000 |
3 |
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
180,206,500 |
|
Marybeth
Miceli Newton, COO
|
|
|
2007 |
4 |
|
$ |
52,083.33 |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
52,083.33 |
|
Brent
Phares, Chief Engineer
|
|
|
2007 |
5 |
|
$ |
65,625 |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
-0- |
|
|
$ |
65,625 |
|
3 Shares
redeemed by Company on May 6, 2008 in exchange for 30,000,000 options
exercisable at 110% of fair market value.
4 Joined
us July 6, 2007.
5 Joined
us June 1, 2007.
Employment
Agreements
On October 1, 2006, we
entered into an Employment Agreement with Robert M. Bernstein, our Chief
Executive Officer, President and Chief Financial Officer, which provides certain
terms and conditions with respect to Mr. Bernstein’s
employment. The Employment Agreement is for a three year
term. Under the Employment Agreement, Mr. Bernstein will be paid an
annual salary of $250,000, with one year of paid severance if he is terminated
without good cause prior to the expiration of the employment term.
Other
Compensation
There are
no annuity, pension or retirement benefits proposed to be paid to officers,
directors, or employees of our company in the event of retirement at normal
retirement date as there was no existing plan as of December 31, 2007 provided
for or contributed to by our company.
Director
Compensation
Our
directors are not compensated for their services, but are entitled for
reimbursement of expenses incurred in attending board of directors
meetings.
Grants
of Plan Based Awards
There
were no grants of plan based awards made in 2007.
Outstanding
Equity Awards at Fiscal Year-End
There
were no outstanding equity awards for our executive officers as of December 31,
2007.
On April
18, 2006, our Board of Directors approved the 2006 Non-Qualified Stock Grant and
Option Plan (the 2006 Plan”) with 100,000 shares of our common stock available
for issuance under the plan. The plan offers selected employees,
directors, and consultants an opportunity to acquire our common stock, and
serves to encourage such persons to remain employed by us and to attract new
employees. As of the date of this prospectus, we have issued all 100,000
shares of common stock under the 2006 Plan.
On
December 1, 2006, our Board of Directors approved the 2006/2007 Non-Qualified
Company Stock Grant and Option Plan (the 2006/2007 Plan”) with 3,000,000 shares
of our common stock available for issuance under the plan. The plan offers
selected employees, directors, and consultants an opportunity to acquire our
common stock, and serves to encourage such persons to remain employed by us and
to attract new employees. As of the date of this prospectus, we have not
issued any options or shares of common stock under the 2006/2007
Plan.
On April
22, 2008, our Board of Directors approved the 2008 Incentive and Nonstatutory
Stock Option Plan (the “2008 Plan”) with 100,000,000 shares of our common stock
available for issuance under the plan. On May 23, 2008, our Board of
Directors amended the 2008 Plan increasing the number of shares of our common
stock available for issuance under the plan to 400,000,000. On
December 4, 2008, our Board of Directors amended the 2008 Plan decreasing the
number of shares of our common stock available for issuance under the plan to
30,400,000. The 2008 Plan offers selected employees, directors, and
consultants an opportunity
to
acquire our common stock, and serves to encourage such persons to remain
employed by us and to attract new employees. On December 4, 2008, our
Board of Directors amended the 2008 Plan decreasing the number of shares of our
common stock available for issuance under the 2008 Plan to
30,400,000. As of the date of this prospectus, we have issued
30,000,000 stock options to employees under the 2008 Plan.
Indemnification
of Directors and Officers
The laws
of the State of Delaware and our Bylaws provide for indemnification of our
directors for liabilities and expenses that they may incur in such
capacities. Under the laws of the State of Delaware and our bylaws,
directors and officers are indemnified with respect to actions taken in good
faith in a manner reasonably believed to be in, or not opposed to, our best
interests, and with respect to any criminal action or proceeding, actions that
the indemnitee had no reasonable cause to believe were
unlawful. Additionally, on November 17, 2006, we entered into an
indemnification agreement with each of our directors. Under the terms of
the indemnification agreements, we agreed to indemnify each director to the
fullest extent permitted by law if the director was or is a party or threatened
to be made a party to any action or lawsuit by reason of the fact that he is or
was a director. The indemnification shall cover all expenses, penalties,
fines and amounts paid in settlement, including attorneys’ fees. A
director will not be indemnified for intentional misconduct for the primary
purpose of his or her own personal benefit.
Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may
be permitted to our directors, officers or control persons pursuant to the
foregoing provisions, we are informed that, in the opinion of the Securities and
Exchange Commission, such indemnification is against public policy as expressed
in the Act and is therefore unenforceable.
Common
Stock
We are
authorized to issue 600,000,000 shares of common stock with a par value of $0.01
per share. As of the date of this prospectus, there are 22,390,410
shares of common stock outstanding, which are held of record by approximately
1,729 stockholders.
The
holders of common stock are entitled to one vote per share on all matters to be
voted upon by the stockholders. Subject to preferences that may be
applicable to any outstanding preferred stock, the holders of common stock are
entitled to receive ratably dividends, if any, as may be declared from time to
time by the Board of Directors out of funds legally available for that
purpose. In the event of our liquidation, dissolution, or winding up,
the holders of common stock are entitled to share ratably in all assets
remaining after payment of liabilities, subject to prior distribution rights of
preferred stock, if any, then outstanding. The common stock has no
preemptive or conversion rights or other subscription rights. There
are no redemption or sinking fund provisions applicable to the common
stock.
Warrants
On August
29, 2008, we issued the following warrants to purchase shares of our common
stock which are being registered herein:
Number
of Warrants
|
Exercise
Price
|
Expiration
Date
|
6,200,200
|
$0.20
|
September
18, 2009
|
5,850,000
|
$0.20
|
September
18, 2011
|
6,000,000
|
$0.10
|
September
15, 2009
|
Convertible
Debentures
On July
31, 2008, we issued a $1,000,000 10% convertible debenture to Kreuzfeld Ltd.
(the “Debenture”). Interest on the Debenture is payable quarterly and
may be paid in either cash or in shares of our common stock, valued at 50% of
the average closing price of our common stock on the ten trading days
immediately prior to such share issuance, at our option. All or any
portion of the amounts due under the Debenture, which matures on December 31,
2011, may be converted at any time, at the option of Kreuzfeld Ltd., into shares
of our common stock at a conversion price equal to the lesser of (i) 50% of the
average closing price of our common stock for the ten trading days immediately
preceding the conversion date, or (ii) $0.10. On August 6, 2008, we
entered into a Registration Rights Agreement with Kreuzfeld Ltd. pursuant to
which we agreed to
file a registration statement with the SEC registering the shares
issuable upon the Debenture’s conversion.
Market
Information
Our
common stock is quoted on the OTC Bulletin Board under the symbol
MTCH. The following table sets forth the high and low bid prices per
share of common stock for the last two fiscal years. These prices
represent inter-dealer quotations without retail markup, markdown, or commission
and may not necessarily represent actual transactions.
|
|
High
|
|
|
Low
|
|
Fiscal
year ended December 31, 2006:
|
|
|
|
|
|
|
First
quarter
|
|
$ |
0.29 |
|
|
$ |
0.09 |
|
Second
quarter
|
|
$ |
0.35 |
|
|
$ |
0.08 |
|
Third
quarter
|
|
$ |
0.10 |
|
|
$ |
0.03 |
|
Fourth
quarter
|
|
$ |
13.80 |
|
|
$ |
0.03 |
|
|
|
|
|
|
|
|
|
|
Fiscal
year ended December 31, 2007:
|
|
|
|
|
|
|
|
|
First
quarter
|
|
$ |
3.70 |
|
|
$ |
0.41 |
|
Second
quarter
|
|
$ |
1.65 |
|
|
$ |
1.01 |
|
Third
quarter
|
|
$ |
1.97 |
|
|
$ |
0.55 |
|
Fourth
quarter
|
|
$ |
0.75 |
|
|
$ |
0.40 |
|
|
|
|
|
|
|
|
|
|
Nine
months ended September 30, 2008
|
|
|
|
|
|
|
|
|
First
quarter
|
|
$ |
0.95 |
|
|
$ |
0.02 |
|
Second
quarter
|
|
$ |
0.03 |
|
|
$ |
0.002 |
|
Third
quarter
|
|
$ |
0.002 |
|
|
$ |
0.001 |
|
The
closing price of our common stock on December 9, 2008 was
$2.10.
Holders
As of the
date of this prospectus, we had 22,390,410 shares of our Class A common stock
issued and outstanding and held by approximately 1,729 holders of
record. The number of record holders was determined from the records
of our transfer agent and does not include beneficial owners of common stock
whose shares are held in the names of various security brokers, dealers, and
registered clearing agencies. The transfer agent for our Class A common
stock is Interwest Transfer Company, Inc., 1981 East 4800 South, Suite 100, Salt
Lake City, Utah 84117.
Dividends
We have
never declared or paid any cash dividends on our common stock. We do not
anticipate paying any cash dividends to stockholders in the foreseeable future.
In addition, any future determination to pay cash dividends will be at the
discretion of the Board of Directors and will be dependent upon our financial
condition, results of operations, capital requirements, and such other factors
as the Board of Directors deem relevant.
The
following table sets forth certain information regarding our shares of
outstanding common stock beneficially owned as of the date hereof by (i) each of
our directors and executive officers, (ii) all directors and executive officers
as a group, and (iii) each other person who is known by us to own beneficially
more than 5% of our common stock based upon 22,390,410 shares of Class A common
stock outstanding.
Name
and Address of
|
Class A Common
Stock
|
Class B Common
Stock
|
Amount
and Nature of
Beneficial
Ownership
|
Percent
Ownership
|
Amount
and Nature of
Beneficial
Ownership
|
Percent
Ownership
of
Class
|
Robert
M. Bernstein, President, CEO, CFO, and Director
|
|
57.3%
|
|
99.5%
|
William
Berks, Vice President and Director
|
2,520
|
*
|
0
|
0%
|
Joel
R. Freedman, Secretary and Director
|
3,505
|
*
|
0
|
0%
|
Marybeth
Miceli, Chief Operating Officer
|
2,040
|
*
|
0
|
0%
|
Brent
Phares, Chief Engineer
|
3,313
|
*
|
0
|
0%
|
All
executive officers and directors as a group (five persons)
|
30,011,450
|
57.3%
|
597,000
|
99.5%
|
Delana
International, Inc.
38
Ru de la Faiencerie L-1510
Luxembourg
|
1,500,000
|
6.7%
|
0
|
0%
|
Bank
Julius Baer & Co. Hong Kong
Hohlstrasse
602 CH-B040
Zurich,
Switzerland
|
|
8.6%
|
0
|
0%
|
1 C/o our address, 11661 San Vicente Blvd.,
Suite 707, Los Angeles, CA 90049, unless otherwise noted.
2 Except as otherwise indicated, we
believe that the beneficial owners of common stock listed above, based on
information furnished by such owners, have sole investment and voting power with
respect to such shares, subject to community property laws where
applicable. Beneficial ownership is determined in accordance with the
rules of the Securities and Exchange Commission and generally includes voting or
investment power with respect to securities. Shares of common stock
subject to options or warrants currently exercisable, or exercisable within 60
days, are deemed outstanding for purposes of computing the percentage of the
person holding such options or warrants, but are not deemed outstanding for
purposes of computing the percentage of any other person.
3
Includes 30,000,000 options to purchase shares of Class A common stock at $0.011
per share expiring on April 22, 2018.
4 Each share of Class B common stock has
2,000 votes on any matter which is brought for shareholders vote. As a
result, Mr. Bernstein holds 1,194,000,000 votes represented by the Class B
common stock, and 97.8% of the overall votes.
5 Includes 1,000,000 shares of common stock
issuable upon exercise of warrants expiring September 18, 2009 at an exercise
price of $0.20 per share.
Kreuzfeld,
Ltd.
c/o
RCB, Tegetthoffstrasse 1, 1015
Vienna,
Austria
|
|
37.8%
|
0
|
0%
|
Montalcino
S.A.
38
Ave de Faiencerie
L-100
Luxembourg
|
2,000,000
|
8.9%
|
0
|
0%
|
RBC
Dexia Investor Services Bank Luxembourg
Hohlstrasse
602 CH-B040
Zurich,
Switzerland
|
3,562,743
|
15.9%
|
0
|
0%
|
Anima
S.G.R.P.A. Rubrica-Anima America
Via
Brera 18 20121
Milano,
Italy
|
|
18.9%
|
0
|
0%
|
Cambridge
Services
c/o
Shirley & Diaz, 45 Street Nueva Urbanizacion Obarrio, Panama City,
Panama
|
|
19.8%
|
0
|
0%
|
Rubrica
Anima Fondattivo
Via
Brera 20121
Milano,
Italy
|
|
9.7%
|
0
|
0%
|
Rubrica
Anima Fondo Trading
Via
Brera 18 20121
Milano,
Italy
|
|
12.6%
|
0
|
0%
|
Discover
Advisory Company
c/o
Horymor Trust Corp. Ltd.,
50
Shirley Street, Nassau, Bahamas
|
6,100,000
|
27.2%
|
0
|
0%
|
Continental
Advisors S.A.
Corso
Alfieri 241 14100 Asti at Italy
|
|
21.4%
|
0
|
0%
|
Palisades
Capital, LLC
c/o
Corporate Legal Services
2224
Main Street
Santa
Monica, CA 90405
|
|
38.7%
|
0
|
0%
|
6 Includes 10,000,000 shares
of common stock underlying $1,000,000 convertible debenture; and 850,000 shares
of common stock issuable upon exercise of warrants expiring September 18, 2011
at an exercise price of $0.20 per share.
7 Includes
2,328,750 shares of common stock issuable upon exercise of warrants expiring
September 18, 2009 at an exercise price of $0.20 per share.
8 Includes 5,000,000 shares of common stock
issuable upon exercise of warrants expiring September 18, 2011 at an exercise
price of $0.20 per share.
9 Includes 1,171,250 shares of common stock
issuable upon exercise of warrants expiring September 18, 2009 at an exercise
price of $0.20 per share.
10 Includes
1,500,000 shares of common stock issuable upon exercise of warrants expiring
September 18, 2009 at an exercise price of $0.20 per share.
11 Includes 6,000,000 shares of common stock
issuable upon exercise of warrants expiring September 18, 2009 at an exercise
price of $0.10 per share.
12 Consists
of 14,157,171 shares of common stock issuable upon conversion of a convertible
debenture as of September 30, 2008.
Hyde
Investments, Ltd.
c/o
Corporate Legal Services
2224
Main Street
Santa
Monica, CA 90405
|
|
49.5%
|
0
|
0%
|
Livingston
Investments, Ltd.
c/o
Corporate Legal Services
2224
Main Street
Santa
Monica, CA 90405
|
|
23.7%
|
0
|
0%
|
13 Consists
of 21,926,298 shares of common stock issuable upon conversion of a convertible
debenture as of September 30, 2008.
14 Consists
of 6,958,483 shares of common stock issuable upon conversion of a convertible
debenture as of September 30, 2008.
All of
our shares of common stock offered under this prospectus may be sold by the
holders. We will not receive any of the proceeds from sales of shares
offered under this prospectus. We will receive $0.20 per share from
the exercise of 12,050,200 warrants and $0.10 per share from the exercise of
6,000,000 warrants which have been granted to date which have been included in
this prospectus.
All
costs, expenses and fees in connection with the registration of the selling
securityholders’ shares will be borne by us. All brokerage
commissions, if any attributable to the sale of shares by selling
securityholders will be borne by such holders.
The
selling securityholders are offering 19,607,943 shares of our common stock,
18,050,200 shares underlying warrants and 10,000,000 shares issuable upon
conversion of debentures pursuant to this prospectus for an aggregate
of 48,829,193 shares. The selling securityholders may sell
common stock at market prices during the term of this offering. The selling
securityholders are deemed “underwriters” within the meaning of the Act in
connection with the sale of their common stock under this prospectus. We will
pay the expenses of registering these shares. The selling securityholders are
not affiliated with broker-dealers. The following table sets forth:
(a) the name of each person who is a selling securityholder; (b) the
number of securities owned by each such person at the time of this offering; and
(c) the number of shares of common stock such person will own after the
completion of this offering.
The
column “Shares Owned After the Offering” gives effect to the sale of all the
shares of common stock being offered by this prospectus.
|
|
Shares
Owned Prior to the Offering
|
Shares
Owned After the Offering
|
Selling
securityholder
|
No.
of Shares Offered
|
Number
|
Percentage
|
Number
|
Percentage
|
Anima
S.G.R.P.A. Rubrica Anima America
Via
Brera 18 20121
Milano,
Italy
|
|
|
18.9%
|
3,100
|
*
|
Bank
Julius Baer & Co. Hong Kong
Hohlstrasse
602 CH-B040
Zurich,
Switzerland
|
|
|
8.6%
|
-0-
|
0%
|
Cambridge
Services, Inc.
c/o
Shirley & Diaz, 45
Street Nueva Urbanizacion Obarrio, Panama City, Panama
|
|
|
19.8%
|
-0-
|
0%
|
1 Consists of 2,328,750 shares of common
stock and 2,328,750 shares of common stock issuable upon exercise of warrants
expiring September 18, 2009 at an exercise price of $0.20.
2 Consists
of 2,331,850 shares of common stock and 2,328,750 shares of common stock
issuable upon exercise of warrants expiring September 18, 2009 at an exercise
price of $0.20.
3 Consists of 1,000,000 shares of common
stock and 1,000,000 shares of common stock issuable upon exercise of warrants
expiring September 18, 2009 at an exercise price of $0.20.
4 Consists of 410,000 shares of common stock
and 5,000,000 shares of common stock issuable upon exercise of warrants expiring
September 18, 2011 at an exercise price of $0.20.
Continental
Advisors S.A.
Corso
Alfieri 241 14100 Asti at Italy
|
|
|
21.4%
|
1,000
|
*
|
Delana International,
Inc.
38
Ru de la Faiencerie L-1510 Luxembourg
|
1,500,000
|
1,500,000
|
6.7%
|
-0-
|
0%
|
Discover
Advisory Company
c/o
Horymor Trust Corp. Ltd., 50 Shirley Street, Nassau,
Bahamas
|
6,100,000
|
6,100,000
|
27.2%
|
-0-
|
0%
|
Kreuzfeld
Ltd.
c/o
RCB, Tegetthoffstrasse 1, 1015
Vienna,
Austria
|
|
|
37.8%
|
1,700,000
|
5.1%
|
Montalcino
S.A.
38
Ave de Faiencerie
L-100
Luxembourg
|
2,000,000
|
2,000,000
|
8.9%
|
-0-
|
0%
|
Patrick
Fischli
UBS
Einsiedeln 216-509011 S 4 Einsiedeln 8840 Switzerland
|
|
|
1.3%
|
-0-
|
0%
|
RBC
Dexia Investor Services Bank Luxembourg
Hohlstrasse
602 CH-B040
Zurich,
Switzerland
|
3,562,743
|
3,562,743
|
15.9%
|
-0-
|
0%
|
Rubrica
Anima Fondattivo
Via
Brera 20121
Milano,
Italy
|
|
|
9.7%
|
-0-
|
0%
|
Rubrica
Anima Fondo Trading
Via
Brera 18 20121
Milano,
Italy
|
|
|
12.6%
|
-0-
|
0%
|
TOTAL
|
47,658,943
|
49,362,243
|
|
1,704,100
|
|
5 Consists of shares of common stock issuable
upon exercise of warrants expiring September 15, 2009 at an exercise price of
$0.10.
6 Consists
of 1,000 shares of common stock and 6,000,000 shares of common stock issuable
upon exercise of warrants expiring September 18, 2009 at an exercise price of
$0.10 per share.
7 Consists of 10,000,000 shares of common
stock underlying $1,000,000 convertible debenture and 850,000 shares of common
stock issuable upon exercise of warrants expiring September 18, 2011 at an
exercise price of $0.20.
8 Consists
of 1,700,000 shares of common stock; 10,000,000 shares of common stock
underlying $1,000,000 convertible debenture; and 850,000 shares of common stock
issuable upon exercise of warrants expiring September 18, 2011 at an exercise
price of $0.20 per share.
9 Consists
of 100,300 shares of common stock and 200,200 shares of common stock issuable
upon exercise of warrants expiring September 18, 2009 at an exercise price of
$0.20.
10 Consists of 1,106,150 shares of common
stock and 1,171,250 shares of common stock issuable upon exercise of warrants
expiring September 18, 2009 at an exercise price of $0.20.
11 Consists of
1,500,000 shares of common stock and 1,500,000 shares of common stock issuable
upon exercise of warrants expiring September 18, 2009 at an exercise price of
$0.20.
*Less than
1%.
The
shares covered by this prospectus may be offered and sold during the term of
this offering by the selling securityholders. The selling
securityholders will act independently of us in making decisions with respect to
the timing, manner and size of each sale. The selling securityholders
may offer and sell the shares from time at market prices as quoted on the
over-the-counter Bulletin Board system throughout the period of the
offering.
The
selling securityholders may sell their shares through registered broker-dealers
by one or more of, or a combination of, the following methods: (a) purchase
by a broker-dealer as principal and resale by such broker-dealer for its own
account through this prospectus; or (b) ordinary brokerage transactions and
transactions in which the broker solicits purchasers. In offering the
shares covered by this prospectus, the selling securityholders and any
broker-dealers who execute sales for the selling securityholders are deemed
“underwriters” within the meaning of the Act in connection with such
sales. Any profits realized by the selling securityholders and the
compensation of any broker-dealer will be deemed to be underwriting discounts
and commissions.
MATECH
CORP.
Financial
Statements and Notes for the Nine and Three Months Ended September 30, 2008 as
compared to the Nine and Three Months Ended September 30, 2007
(unaudited)
Financial
Statements and Notes for the Year Ended December 31, 2007 as compared to the
Year Ended December 31, 2006 (audited)
Financial Statements and Notes for the Nine and
Three Months Ended September 30, 2008 as compared to the Nine and Three Months
Ended September 30, 2007 (unaudited)
MATECH
CORP.
|
|
(A
Development Stage Company)
|
|
|
|
|
|
CONDENSED
CONSOLIDATED BALANCE SHEET
|
|
|
|
|
|
|
|
September
30,
|
|
|
|
2008
|
|
|
|
(Unaudited)
|
|
ASSETS
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
Cash
and cash equivalents
|
|
$ |
441,076 |
|
Accounts
receivable
|
|
|
15,620 |
|
Inventories
|
|
|
156,054 |
|
Prepaid
expenses and other current assets
|
|
|
70,423 |
|
|
|
|
|
|
Total
current assets
|
|
|
683,173 |
|
|
|
|
|
|
Property
and equipment, net
|
|
|
84,590 |
|
Deferred
loan fees
|
|
|
356,708 |
|
Intangible
assets, net
|
|
|
2,033 |
|
Deposit
|
|
|
2,348 |
|
|
|
|
|
|
|
|
$ |
1,128,852 |
|
MATECH
CORP.
|
|
|
|
(A
Development Stage Company)
|
|
|
|
|
|
|
|
CONDENSED
CONSOLIDATED BALANCE SHEET - Continued
|
|
|
|
|
|
|
|
|
September
30,
|
|
|
|
2008
|
|
|
|
(Unaudited)
|
|
LIABILITIES
AND STOCKHOLDERS' DEFICIT
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
Accounts payable and accrued expenses
|
|
$ |
646,208 |
|
Current portion of research and development sponsorship
payable
|
|
|
25,000 |
|
Notes payable - current portion
|
|
|
294,567 |
|
Total current liabilities
|
|
|
965,775 |
|
|
|
|
|
|
Accrued legal settlement
|
|
|
222,852 |
|
Research and development sponsorship payable, net of current
portion
|
|
|
768,934 |
|
Convertible debentures and accrued interest payable, net of
discounts
|
|
|
1,280,201 |
|
Derivative and warrant liabilities
|
|
|
3,500,035 |
|
|
|
|
5,772,022 |
|
|
|
|
|
|
Total liabilities
|
|
|
6,737,797 |
|
|
|
|
|
|
Minority interest in consolidated subsidiary
|
|
|
825 |
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
Stockholders' deficit:
|
|
|
|
|
Class A preferred stock, $0.001 par value, liquidation
preference
|
|
|
|
|
of $720 per share; 350,000 shares authorized; 337 shares
issued
|
|
|
|
|
and outstanding as of September 30, 2008
|
|
|
- |
|
Class
B preferred stock, $0.001 par value, liquidation preference
of
|
|
|
|
|
$10,000 per share; 15 shares authorized; none issued
and
|
|
|
|
|
outstanding as of September 30, 2008
|
|
|
- |
|
Class C preferred stock, $0.001 par value, liquidation preference
of
|
|
|
|
|
$0.001 per share; 25,000,000 shares authorized; 1,517 shares
issued
|
|
|
|
|
and outstanding as of September 30,2008
|
|
|
1 |
|
Class D preferred stock, $0.001 par value, liquidation preference
of
|
|
|
|
|
$0.001 per share; 20,000,000 shares authorized; none shares
issued
|
|
|
|
|
and outstanding as of September 30,2008
|
|
|
- |
|
Class E convertible preferred stock, $0.001 par value, no
liquidation
|
|
|
|
|
preference; 60,000 shares authorized; 49,200 shares issued
and
|
|
|
|
|
outstanding as of September 30,2008
|
|
|
49 |
|
Class A Common Stock, $0.001 par value, 600,000,000 shares
|
|
|
|
|
authorized; 205,736,018 shares issued and 186,567,253 shares
outstanding
|
|
|
|
at
September 30,2008
|
|
|
186,567 |
|
Class B Common Stock, $0.001 par value, 600,000 shares
authorized,
|
|
|
|
|
issued
and outstanding as of September 30,2008
|
|
|
600 |
|
Warrants subscribed
|
|
|
10,000 |
|
Additional paid-in-capital
|
|
|
326,742,387 |
|
Deficit accumulated during the development stage
|
|
|
(332,547,374 |
) |
Treasury stock (200,000 shares at cost at September 30,
2008)
|
|
|
(2,000 |
) |
|
|
|
|
|
Total stockholders' deficit
|
|
|
(5,609,770 |
) |
|
|
|
|
|
|
|
$ |
1,128,852 |
|
MATECH
CORP.
|
|
(A
Development Stage Company)
|
|
|
|
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
From
October 21, 1983
|
|
|
|
For
the Three Months Ended
|
|
|
For
the Nine Months Ended
|
|
|
(Inception)
|
|
|
|
September
30,
|
|
|
September
30,
|
|
|
through
|
|
|
|
2007
|
|
|
2008
|
|
|
2007
|
|
|
2008
|
|
|
September
30, 2008
|
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
5,392,085 |
|
Revenue
from bridge testing
|
|
|
80,000 |
|
|
|
29,269 |
|
|
|
146,745 |
|
|
|
30,359 |
|
|
|
348,983 |
|
Other
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
274,125 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
revenues
|
|
|
80,000 |
|
|
|
29,269 |
|
|
|
146,745 |
|
|
|
30,359 |
|
|
|
6,015,193 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Costs
and expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development
|
|
|
21,266 |
|
|
|
113,588 |
|
|
|
3,533,343 |
|
|
|
423,428 |
|
|
|
20,986,417 |
|
General
and administrative
|
|
|
20,133,368 |
|
|
|
773,334 |
|
|
|
82,608,673 |
|
|
|
26,619,102 |
|
|
|
330,114,343 |
|
Modification
of research and development sponsorship agreement
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
5,963,120 |
|
Loss
on Settlement of lawsuits
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
1,267,244 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
Costs and expenses
|
|
|
20,154,634 |
|
|
|
886,922 |
|
|
|
86,142,016 |
|
|
|
27,042,530 |
|
|
|
358,331,124 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
from operations
|
|
|
(20,074,634 |
) |
|
|
(857,653 |
) |
|
|
(85,995,271 |
) |
|
|
(27,012,171 |
) |
|
|
(352,315,931 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
on modification of convertible debt
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(964,730 |
) |
|
|
(378,485 |
) |
Loss
on subscription receivables
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(1,368,555 |
) |
Interest
expense
|
|
|
(423,510 |
) |
|
|
(831,678 |
) |
|
|
(2,014,161 |
) |
|
|
(1,808,697 |
) |
|
|
(13,548,890 |
) |
Other-than-temporary
impairment of marketable securities available for sale
|
|
|
(2,310,000 |
) |
|
|
- |
|
|
|
(10,254,000 |
) |
|
|
- |
|
|
|
(9,785,947 |
) |
Net
unrealized and realized loss of marketable securities
|
|
|
(335 |
) |
|
|
|
|
|
|
(612,553 |
) |
|
|
(8 |
) |
|
|
(9,398,226 |
) |
Change
in fair value of investments derivative liability
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(210,953 |
) |
Change
in fair value of derivative and warrant liabilities
|
|
|
(8,414,694 |
) |
|
|
72,975,655 |
|
|
|
14,505,323 |
|
|
|
10,431,555 |
|
|
|
54,018,644 |
|
Interest
income
|
|
|
19,304 |
|
|
|
356 |
|
|
|
35,270 |
|
|
|
15,879 |
|
|
|
482,761 |
|
Other
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(25,992 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
income (expense), net
|
|
|
(11,129,235 |
) |
|
|
72,144,333 |
|
|
|
1,659,879 |
|
|
|
7,673,999 |
|
|
|
19,784,357 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income
(loss) before provision for income taxes
|
|
|
(31,203,869 |
) |
|
|
71,286,680 |
|
|
|
(84,335,392 |
) |
|
|
(19,338,172 |
) |
|
|
(332,531,574 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision
for income taxes
|
|
|
- |
|
|
|
- |
|
|
|
(800 |
) |
|
|
(800 |
) |
|
|
(15,800 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
Income (loss)
|
|
$ |
(31,203,869 |
) |
|
$ |
71,286,680 |
|
|
$ |
(84,336,192 |
) |
|
$ |
(19,338,972 |
) |
|
$ |
(332,547,374 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Per
share data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
and diluted net loss per share
|
|
$ |
(0.25 |
) |
|
$ |
0.41 |
|
|
$ |
(0.83 |
) |
|
$ |
(0.12 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average Class A common shares outstanding - basic and
diluted
|
|
|
124,276,444 |
|
|
|
175,239,753 |
|
|
|
101,671,169 |
|
|
|
156,873,303 |
|
|
|
|
|
MATECH
CORP.
|
|
|
|
|
|
|
|
|
|
(A
Development Stage Company)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED
STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
From
October 21, 1983
|
|
|
|
For
the Nine Months Ended
|
|
|
(Inception)
|
|
|
|
September
30,
|
|
|
through
|
|
|
|
2007
|
|
|
2008
|
|
|
September
30, 2008
|
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
Net
income (loss)
|
|
$ |
(31,203,869 |
) |
|
$ |
71,286,680 |
|
|
$ |
(332,547,374 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
Temporary
increase (decrease) in market
|
|
|
|
|
|
|
|
|
|
|
|
|
value of securities available for sale
|
|
|
- |
|
|
|
|
|
|
|
- |
|
Reclassification
to other-than-temporary
|
|
|
|
|
|
|
|
|
|
|
|
|
impairment
of marketable securities
|
|
|
|
|
|
|
|
|
|
|
|
|
available
for sale
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
comprehensive income (loss)
|
|
$ |
(31,203,869 |
) |
|
$ |
71,286,680 |
|
|
$ |
(332,547,374 |
) |
MATECH
CORP.
|
|
(A
Development Stage Company)
|
|
|
|
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
From
October 21, 1983
|
|
|
|
For
the Nine Months Ended
|
|
|
(Inception)
|
|
|
|
September
30,
|
|
|
through
|
|
|
|
2007
|
|
|
2008
|
|
|
September
30, 2008
|
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
(Unaudited)
|
|
|
|
(Restated)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
flows from operating activities:
|
|
|
|
|
|
|
|
|
|
Net
loss
|
|
$ |
(84,336,192 |
) |
|
$ |
(19,338,972 |
) |
|
$ |
(332,547,374 |
) |
Adjustments
to reconcile net loss to net cash used in
operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
(Gain)
loss on modification of convertible debt
|
|
|
- |
|
|
|
964,730 |
|
|
|
378,485 |
|
Impairment
loss
|
|
|
19,294,877 |
|
|
|
- |
|
|
|
21,391,528 |
|
Loss
on charge off of subscription receivables
|
|
|
- |
|
|
|
- |
|
|
|
1,368,555 |
|
Issuance
of common stock for services
|
|
|
19,519,168 |
|
|
|
4,729,541 |
|
|
|
211,214,381 |
|
Increase
in debt for services and fees
|
|
|
- |
|
|
|
|
|
|
|
4,456,625 |
|
Officer's
stock based compensation
|
|
|
45,000,000 |
|
|
|
19,885,333 |
|
|
|
86,460,675 |
|
Issuance
of common stock for modification of
|
|
|
|
|
|
|
|
|
|
|
|
|
research and development sponsorship agreement
|
|
|
- |
|
|
|
- |
|
|
|
7,738,400 |
|
Change
in fair value of derivative and warrant liabilities
|
|
|
(14,505,323 |
) |
|
|
(10,431,555 |
) |
|
|
(51,783,444 |
) |
Net
realized and unrealized loss on marketable securities
|
|
|
612,553 |
|
|
|
- |
|
|
|
7,895,705 |
|
Other-than-temporary
impairment of marketablesecurities available for
sale
|
|
|
10,254,000 |
|